_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
503544790,7/16/2014 20:23:31,,1324459260,7/16/2014 20:23:17,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,Na,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 20:30:47,,1324462571,7/16/2014 20:30:27,clixsense,1,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],(6/11 GENITAL DYSPLASIA,asd,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 20:31:07,,1324462693,7/16/2014 20:30:39,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],DYSPLASIA,N/A,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 20:38:48,,1324465745,7/16/2014 20:38:08,clixsense,1,15189335,GBR,H9,London,188.29.165.101,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detected,Na,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 20:47:19,,1324469173,7/16/2014 20:46:57,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/a,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 21:00:16,,1324474606,7/16/2014 20:59:44,instagc,1,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],INTRAEPITHELIAL,NONE,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 21:09:56,,1324480382,7/16/2014 21:09:43,instagc,1,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 21:28:51,,1324489719,7/16/2014 21:28:04,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA,n/a,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 22:42:52,,1324518594,7/16/2014 22:42:31,clixsense,1,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],positive study group,N/A,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 23:12:21,,1324529610,7/16/2014 23:10:15,clixsense,1,11338264,CAN,ON,Aurora,184.148.114.225,[OTHER],[OTHER],DYSPLASIA or CERVICAL INTRAEPITHELIAL,N/a,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/16/2014 23:26:02,,1324535968,7/16/2014 23:25:52,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/17/2014 03:58:10,,1324768846,7/17/2014 03:57:26,neodev,1,20929875,USA,MA,Boston,96.233.18.114,[IS_A],[IS_A],GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA,N/A,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/17/2014 04:17:55,,1324786046,7/17/2014 04:17:23,instagc,1,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/a,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/17/2014 04:41:08,,1324806964,7/17/2014 04:40:24,elite,1,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544790,7/17/2014 05:12:31,,1324836070,7/17/2014 05:11:08,vivatic,1,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],positive study group who did not have patients with patients with,N/A,206,227,222,269,-1,RO-disease_has_finding,901802-FS1,"Within a positive study group totalling 71 patients, HPV (6/11 or 16/18) was detected in cervical scrapes from 24% of 41 patients who did not have visible genital dysplasia, 30% of 27 patients with visible GENITAL DYSPLASIA or CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I and in 1 of 3 patients with past CIN II/III.",GENITAL DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) I
503544791,7/16/2014 20:28:35,,1324461558,7/16/2014 20:28:10,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],reduction model,N/A,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/16/2014 20:32:15,,1324463136,7/16/2014 20:31:44,instagc,1.0,13763729,USA,"","",75.182.89.225,[PART_OF],[PART_OF],ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS,N/A,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/16/2014 20:33:22,,1324463537,7/16/2014 20:33:03,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS,All one term,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/16/2014 21:18:40,,1324485329,7/16/2014 21:18:12,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[SYMPTOM],[SYMPTOM],reduction model,N/A,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/16/2014 21:19:25,,1324485581,7/16/2014 21:18:18,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANXIETY reduction model OBSESSIVE COMPULSIVE NEUROSIS,n/a,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/16/2014 21:36:05,,1324492555,7/16/2014 21:35:11,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[TREATS],[TREATS],reduction model of,n/a,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/16/2014 22:59:24,,1324525004,7/16/2014 22:58:04,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[NONE],[NONE],n/a,no information to support relationship,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/16/2014 23:17:17,,1324531546,7/16/2014 23:16:22,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS,N/A,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/17/2014 00:09:42,,1324554742,7/17/2014 00:09:06,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],reduction model of,N/A,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/17/2014 02:30:30,,1324682477,7/17/2014 02:29:55,prodege,1,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],of,none,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/17/2014 03:59:55,,1324770720,7/17/2014 03:58:12,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",ANXIETY reduction OBSESSIVE COMPULSIVE NEUROSIS,N/A,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/17/2014 04:09:54,,1324779323,7/17/2014 04:09:09,elite,1.0,27788262,USA,"","",172.129.33.133,[PART_OF],[PART_OF],of,N/A,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/17/2014 04:22:57,,1324790739,7/17/2014 04:22:47,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],model,N/A,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/17/2014 05:29:13,,1324850280,7/17/2014 05:28:33,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],model,N/A,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544791,7/17/2014 05:33:16,,1324853169,7/17/2014 05:32:22,clixsense,1,27969116,NLD,"","",91.213.37.165,[SYMPTOM],[SYMPTOM],reduction model of inadequate.,the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.,79,106,85,135,-1,RO-has_definitional_manifestation,904918-FS1,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
503544792,7/16/2014 20:27:46,,1324461154,7/16/2014 20:27:33,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,Na,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/16/2014 20:33:14,,1324463509,7/16/2014 20:32:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/16/2014 20:59:05,,1324474003,7/16/2014 20:58:40,clixsense,1,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,N/A,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/16/2014 21:28:00,,1324489309,7/16/2014 21:27:16,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],findings OHSS include ASCITES,n/a,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/16/2014 21:29:59,,1324490189,7/16/2014 21:29:17,eup_slw,1,20900720,USA,ID,Boise,97.121.0.39,[SYMPTOM],[SYMPTOM],OHSS include ASCITES,N/A,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/16/2014 21:57:40,,1324500925,7/16/2014 21:57:12,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[SYMPTOM],[SYMPTOM],findings of OHSS include,na,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/16/2014 22:30:41,,1324513598,7/16/2014 22:30:04,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],laboratory findings,N/A,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/16/2014 22:47:33,,1324520464,7/16/2014 22:46:46,bitcoinget,1,28222930,USA,IL,Mattoon,206.166.56.30,[SYMPTOM],[SYMPTOM],findings include,na,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/16/2014 23:05:14,,1324527083,7/16/2014 23:04:51,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],"findings of OHSS include ASCITES pleural effusion,",N/A,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/16/2014 23:11:32,,1324529263,7/16/2014 23:10:54,neodev,1,15848372,AUS,02,Jannali,27.96.208.89,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",laboratory findings of,n/a,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/17/2014 01:24:38,,1324616904,7/17/2014 01:23:47,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,not applicable,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/17/2014 02:05:38,,1324658155,7/17/2014 02:04:16,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],physical and laboratory findings,n/a,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/17/2014 02:18:41,,1324670710,7/17/2014 02:18:18,clixsense,1,17548588,CAN,ON,New Hamburg,99.241.226.64,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"OHSS include weight gain, ovarian enlargement, ASCITES",n/a,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/17/2014 02:26:37,,1324678566,7/17/2014 02:25:44,rewardsspot,1,17763704,USA,IL,Chicago,67.212.175.123,[PART_OF],[PART_OF],OHSS ASCITES,n/a,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544792,7/17/2014 04:07:46,,1324777483,7/17/2014 04:06:59,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[SYMPTOM],[SYMPTOM],Other physical and laboratory findings of OHSS include,N/a,89,42,95,46,1,RO-has_manifestation,906261-FS1,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS
503544793,7/16/2014 20:31:44,,1324462948,7/16/2014 20:31:21,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",IBUPROFEN,asd,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/16/2014 20:32:27,,1324463242,7/16/2014 20:32:07,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],IBUPROFEN does not enhance INFLAMMATION,N/A,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/16/2014 20:55:50,,1324472621,7/16/2014 20:54:33,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],IBUPROFEN,NONE,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/16/2014 20:57:58,,1324473415,7/16/2014 20:57:34,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[TREATS],[TREATS],IBUPROFEN enhance INFLAMMATION,N/A,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/16/2014 21:25:18,,1324488159,7/16/2014 21:24:24,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],none,no effects,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/16/2014 21:46:02,,1324496491,7/16/2014 21:45:35,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SIDE_EFFECT],[SIDE_EFFECT],enhance,N/A,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/16/2014 22:24:34,,1324510902,7/16/2014 22:24:21,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],metabolite,N/A,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/16/2014 22:32:07,,1324514127,7/16/2014 22:31:45,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],previous studies,N/A,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/16/2014 23:11:36,,1324529280,7/16/2014 23:10:37,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PREVENTS],[PREVENTS],IBUPROFEN reparixin does not enhance INFLAMMATION,N/A,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/17/2014 01:10:31,,1324603720,7/17/2014 01:09:46,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],does not enhance,n/a,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/17/2014 01:33:22,,1324626151,7/17/2014 01:32:33,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],IBUPROFEN INFLAMMATION,n/a,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/17/2014 02:10:17,,1324662743,7/17/2014 02:09:45,clixsense,1.0,17548588,CAN,ON,New Hamburg,99.241.226.64,[TREATS],[TREATS],IBUPROFEN reparixin does INFLAMMATION,n/a,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/17/2014 04:16:20,,1324784678,7/17/2014 04:16:08,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],enhance,N/A,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/17/2014 04:21:14,,1324789113,7/17/2014 04:20:09,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[OTHER],[OTHER],does not enhance,N/a,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544793,7/17/2014 04:24:57,,1324792597,7/17/2014 04:24:35,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[NONE],[NONE],N/A,IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,89,52,100,61,1,RO-may_treat,908045-FS1,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN
503544794,7/16/2014 20:24:19,,1324459571,7/16/2014 20:24:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],"treatment,",N/A,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/16/2014 20:35:15,,1324464274,7/16/2014 20:34:59,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],"treatment,",N/A,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/16/2014 20:59:43,,1324474312,7/16/2014 20:59:20,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[CAUSES],[CAUSES],BIPOLAR DISORDER,NONE,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/16/2014 21:03:15,,1324476438,7/16/2014 21:02:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],has been shown,N/A,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/16/2014 22:27:23,,1324512164,7/16/2014 22:26:48,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],"treatment, initially considered specific BIPOLAR",N/A,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/16/2014 22:37:38,,1324516690,7/16/2014 22:37:10,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],"treatment,",N/A,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/16/2014 23:07:06,,1324527705,7/16/2014 23:06:41,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],"treatment,",n/a,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/16/2014 23:09:01,,1324528315,7/16/2014 23:08:39,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],"treatment, initially considered specific for",na,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/16/2014 23:38:19,,1324541294,7/16/2014 23:36:13,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],"treatment,",N/A,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/17/2014 00:12:05,,1324555696,7/17/2014 00:10:56,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],"treatment,",N/A,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/17/2014 00:30:38,,1324566414,7/17/2014 00:29:54,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[TREATS],[TREATS],"treatment, considered specific for",N/A,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/17/2014 01:13:43,,1324606684,7/17/2014 01:13:33,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],"treatment,",N/A,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/17/2014 01:45:12,,1324637786,7/17/2014 01:43:21,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],LITHIUM BIPOLAR DISORDER,n/a,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/17/2014 02:06:57,,1324659555,7/17/2014 02:06:05,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],LITHIUM BIPOLAR DISORDER,n/a,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544794,7/17/2014 02:09:25,,1324662002,7/17/2014 02:09:08,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],"treatment,",n/a,53,0,68,7,1,RO-may_treat,908289-FS1,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM
503544795,7/16/2014 20:31:01,,1324462668,7/16/2014 20:30:04,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],reduces the occurrence of delayed,N/A,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/16/2014 20:31:42,,1324462947,7/16/2014 20:31:25,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],reduces the occurrence,N/A,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/16/2014 20:48:39,,1324469827,7/16/2014 20:46:49,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],serotonin,NONE,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/16/2014 20:53:59,,1324472007,7/16/2014 20:50:55,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[TREATS],[TREATS],continuation of,Na,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/16/2014 21:52:17,,1324498890,7/16/2014 21:51:49,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],reduces the occurrence of,na,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/16/2014 22:14:26,,1324506781,7/16/2014 22:13:37,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],continuation GRANISETRON reduces occurrence delayed EMESIS,n/a,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/16/2014 22:34:05,,1324514884,7/16/2014 22:33:55,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/16/2014 22:43:19,,1324518745,7/16/2014 22:42:53,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],object of the study,N/A,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/16/2014 22:59:30,,1324525046,7/16/2014 22:59:01,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],after 24 h reduces the occurrence of delayed,na,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/17/2014 00:52:23,,1324586356,7/17/2014 00:51:33,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[TREATS],[TREATS],reduces the occurrence,N/A,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/17/2014 01:31:19,,1324623925,7/17/2014 01:30:32,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],reduces occurrence,not applicable,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/17/2014 02:01:23,,1324653827,7/17/2014 02:00:27,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PREVENTS],[PREVENTS],GRANISETRON EMESIS,n/a,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/17/2014 02:17:08,,1324669048,7/17/2014 02:16:41,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],reduces,none,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/17/2014 03:57:25,,1324768048,7/17/2014 03:56:04,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[TREATS],[TREATS],continuation of GRANISETRON reduces occurrence delayed EMESIS,N/A,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544795,7/17/2014 04:16:58,,1324785193,7/17/2014 04:16:38,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],reduces,N/A,344,287,349,298,1,RO-may_prevent,907359-FS1,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON
503544796,7/16/2014 20:21:57,,1324458538,7/16/2014 20:21:39,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],were treated with,N/A,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/16/2014 20:22:34,,1324458860,7/16/2014 20:22:15,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treated with,n/a,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/16/2014 20:23:21,,1324459194,7/16/2014 20:23:06,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],PARKINSON'S DISEASE treated with LEVODOPA,N/A,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/16/2014 20:24:33,,1324459666,7/16/2014 20:24:19,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],were treated with,n/a,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/16/2014 20:30:11,,1324462319,7/16/2014 20:29:56,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treated,N/A,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/16/2014 21:31:48,,1324490790,7/16/2014 21:31:23,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],PARKINSON'S DISEASE treated LEVODOPA,n/a,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/16/2014 22:27:35,,1324512243,7/16/2014 22:27:18,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],treated with,na,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/16/2014 23:17:21,,1324531586,7/16/2014 23:16:50,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[TREATS],[TREATS],treated,n/a,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/17/2014 01:30:31,,1324623138,7/17/2014 01:30:10,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treated with,not applicable,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/17/2014 01:49:50,,1324642346,7/17/2014 01:46:38,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[TREATS],[TREATS],PARKINSON'S DISEASE treated LEVODOPA,N/A,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/17/2014 01:59:59,,1324652571,7/17/2014 01:59:48,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treated with,n/a,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/17/2014 04:06:09,,1324776111,7/17/2014 04:04:40,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[OTHER],[OTHER],were treated with,N/a,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/17/2014 04:23:27,,1324791241,7/17/2014 04:23:13,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],treated,N/A,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/17/2014 04:41:38,,1324807420,7/17/2014 04:41:10,elite,1.0,27788262,USA,"","",172.129.33.133,[TREATS],[TREATS],were treated with,N/A,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544796,7/17/2014 05:14:18,,1324837893,7/17/2014 05:13:57,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treated with,N/A,27,65,45,73,1,RO-may_treat,908327-FS1,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
503544797,7/16/2014 20:23:57,,1324459376,7/16/2014 20:23:37,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],can be treated immediately with,n/a,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/16/2014 20:30:38,,1324462538,7/16/2014 20:30:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],can be treated immediately with,N/A,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/16/2014 20:32:48,,1324463369,7/16/2014 20:32:41,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],can be treated immediately,N/A,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/16/2014 20:34:58,,1324464176,7/16/2014 20:34:44,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treated,N/A,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/16/2014 21:46:27,,1324496643,7/16/2014 21:45:47,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],can be treated with,na,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/16/2014 22:44:32,,1324519143,7/16/2014 22:44:11,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],treated with,na,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/16/2014 22:46:31,,1324519977,7/16/2014 22:46:09,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],treated immediately,N/A,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/16/2014 23:00:34,,1324525370,7/16/2014 23:00:15,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],HYPOGLYCEMIA can be treated with GLUCAGON,N/A,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/16/2014 23:40:47,,1324542217,7/16/2014 23:40:33,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treated,N/A,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/17/2014 00:24:45,,1324561606,7/17/2014 00:24:29,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],can be treated immediately with,N/A,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/17/2014 01:13:32,,1324606451,7/17/2014 01:13:24,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],treated,N/A,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/17/2014 01:25:28,,1324617655,7/17/2014 01:24:53,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[TREATS],[TREATS],treated,N/A,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/17/2014 01:38:18,,1324631068,7/17/2014 01:36:52,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],HYPOGLYCEMIA GLUCAGON,n/a,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/17/2014 02:16:40,,1324668701,7/17/2014 02:16:13,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treated,none,55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544797,7/17/2014 04:11:35,,1324780797,7/17/2014 04:10:58,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[TREATS],[TREATS],can be treated,"because of:

 HYPOGLYCEMIA can be treated immediately with GLUCAGON",55,100,66,108,1,RO-may_treat,907911-FS1,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
503544798,7/16/2014 20:22:06,,1324458620,7/16/2014 20:21:55,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treatment,Na,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 20:29:04,,1324461783,7/16/2014 20:27:18,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[TREATS],[TREATS],treatment,Na,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 20:29:08,,1324461813,7/16/2014 20:28:38,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],in the treatment of,n/a,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 20:32:40,,1324463338,7/16/2014 20:32:28,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],AMOXICILLIN in treatment of ACUTE MAXILLARY SINUSITIS,N/A,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 20:40:31,,1324466474,7/16/2014 20:40:07,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],ACUTE,asd,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 20:52:09,,1324471241,7/16/2014 20:51:52,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MAXILLARY,NONE,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 20:54:43,,1324472280,7/16/2014 20:53:44,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],in the treatment of,N/A,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 21:20:32,,1324486051,7/16/2014 21:20:05,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],AMOXICILLIN treatment of ACUTE MAXILLARY SINUSITIS,n/a,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 21:20:44,,1324486125,7/16/2014 21:19:53,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[TREATS],[TREATS],the treatment,n/a,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 21:46:29,,1324496656,7/16/2014 21:46:19,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[TREATS],[TREATS],treatment,N/A,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 22:35:18,,1324515513,7/16/2014 22:35:00,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],treatment,N/A,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 22:36:23,,1324516084,7/16/2014 22:36:12,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],treatment,N/A,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 23:03:27,,1324526396,7/16/2014 23:02:58,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,N/A,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 23:16:26,,1324531154,7/16/2014 23:15:31,clixsense,1.0,11338264,CAN,ON,Aurora,184.148.114.225,[TREATS],[TREATS],treatment of ACUTE MAXILLARY SINUSITIS,N/a,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544798,7/16/2014 23:31:18,,1324538111,7/16/2014 23:30:50,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,77,45,101,56,1,RO-may_treat,907639-FS1,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
503544799,7/16/2014 20:28:38,,1324461586,7/16/2014 20:28:24,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],ATOPIC DISEASES (mostly ATOPIC DERMATITIS,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/16/2014 20:30:49,,1324462590,7/16/2014 20:30:13,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],(mostly,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/16/2014 21:31:20,,1324490630,7/16/2014 21:29:46,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[IS_A],[IS_A],occurrence of (mostly,n/a,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/16/2014 21:40:29,,1324494209,7/16/2014 21:40:13,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],(mostly,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/16/2014 21:52:46,,1324499121,7/16/2014 21:51:18,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[IS_A],[IS_A],development included ATOPIC DISEASES ATOPIC DERMATITIS,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/16/2014 22:37:18,,1324516520,7/16/2014 22:36:56,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",(mostly,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/16/2014 22:42:30,,1324518474,7/16/2014 22:41:56,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",included familial occurrence,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/16/2014 23:10:47,,1324528967,7/16/2014 23:10:04,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],(mostly,na,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/16/2014 23:30:21,,1324537693,7/16/2014 23:28:19,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],(mostly ATOPIC DERMATITIS,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/17/2014 02:25:42,,1324677501,7/17/2014 02:23:03,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC DISEASES ATOPIC DERMATITIS,n/a,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/17/2014 03:29:55,,1324741436,7/17/2014 03:28:26,instagc,1,19636746,USA,NY,Andover,192.182.216.225,[IS_A],[IS_A],(mostly,na,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/17/2014 03:48:26,,1324759300,7/17/2014 03:47:58,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[IS_A],[IS_A],DERMATITIS,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/17/2014 04:12:20,,1324781354,7/17/2014 04:11:36,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[IS_A],[IS_A],(mostly,"because

included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS",146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/17/2014 04:17:13,,1324785407,7/17/2014 04:16:59,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(mostly,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544799,7/17/2014 05:18:54,,1324842058,7/17/2014 05:18:33,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],(mostly,N/A,146,122,162,137,-1,RO-cause_of,900445-FS1,A significant effect of the constitutional factor on the development of atopic dermatitis included familial occurrence of ATOPIC DISEASES (mostly ATOPIC DERMATITIS,ATOPIC DERMATITIS,ATOPIC DISEASES
503544800,7/16/2014 20:30:19,,1324462373,7/16/2014 20:29:33,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[TREATS],[TREATS],chemically induced,Na,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/16/2014 20:32:27,,1324463243,7/16/2014 20:32:03,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[OTHER],[OTHER],form,N/A,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/16/2014 20:46:39,,1324468884,7/16/2014 20:46:05,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],form of a chemically induced guinea pig line,N/A,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/16/2014 21:29:16,,1324489894,7/16/2014 21:28:04,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[CAUSES],[CAUSES],ASCITES form HEPATOMA,N/A,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/16/2014 21:33:45,,1324491583,7/16/2014 21:33:13,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",induced guinea pig,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/16/2014 21:39:09,,1324493611,7/16/2014 21:38:10,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[PART_OF],[PART_OF],form of a,n/a,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/16/2014 21:43:25,,1324495352,7/16/2014 21:42:14,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],chemically induced,N/A,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/16/2014 22:23:52,,1324510660,7/16/2014 22:23:38,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/16/2014 23:07:11,,1324527714,7/16/2014 23:06:25,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[PART_OF],[PART_OF],form of a chemically induced,N/A,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/16/2014 23:14:55,,1324530554,7/16/2014 23:13:23,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[MANIFESTATION] [PART_OF] [LOCATION],"[LOCATION]
[MANIFESTATION]
[PART_OF]",form of,n/a,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/17/2014 00:09:05,,1324554521,7/17/2014 00:07:12,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[PART_OF],[PART_OF],form of a,N/A,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/17/2014 01:14:47,,1324607442,7/17/2014 01:14:38,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[MANIFESTATION],[MANIFESTATION],induced,N/A,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/17/2014 01:19:31,,1324611854,7/17/2014 01:19:13,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[CAUSES],[CAUSES],form of a chemically induced guinea pig,N/A,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/17/2014 01:21:02,,1324613124,7/17/2014 01:20:32,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],was resistant to killing in vitro,n/a,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544800,7/17/2014 01:56:38,,1324649162,7/17/2014 01:55:14,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],form of,n/a,4,52,10,60,-1,RO-disease_may_have_finding,902866-FS1,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
503544801,7/16/2014 20:26:06,,1324460352,7/16/2014 20:25:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],other,Na,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/16/2014 20:29:55,,1324462199,7/16/2014 20:29:34,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],SITU,N/A,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/16/2014 20:32:10,,1324463106,7/16/2014 20:31:47,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CONTRAINDICATES],[CONTRAINDICATES],(SEVERE DYSPLASIA,asd,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/16/2014 21:08:15,,1324479210,7/16/2014 21:07:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],showed,N/A,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/16/2014 22:29:26,,1324513058,7/16/2014 22:28:42,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],two premalignant lesions showed of which one and the other,N/A,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/16/2014 22:40:43,,1324517911,7/16/2014 22:39:32,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],two showed,na,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/16/2014 22:44:20,,1324519096,7/16/2014 22:43:20,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CONTRAINDICATES],[CONTRAINDICATES],showed absence,N/A,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/16/2014 23:08:38,,1324528218,7/16/2014 23:08:00,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/16/2014 23:10:36,,1324528882,7/16/2014 23:09:39,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",(CARCINOMA IN SITU and (SEVERE DYSPLASIA showed expression.,N/A,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/17/2014 01:23:13,,1324615470,7/17/2014 01:22:35,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[OTHER],[OTHER],and the other,N/A,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/17/2014 02:31:22,,1324683443,7/17/2014 02:30:54,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/17/2014 04:04:39,,1324774886,7/17/2014 04:03:40,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Only two premalignant lesions showed absence,N/a,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/17/2014 04:13:03,,1324782016,7/17/2014 04:12:22,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[NONE],[NONE],N/A,N/A,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/17/2014 04:18:21,,1324786466,7/17/2014 04:17:58,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],hypermethylated,N/A,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544801,7/17/2014 04:39:13,,1324805334,7/17/2014 04:37:32,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.,165,78,180,95,-1,RO-disease_has_finding,901932-FS1,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
503544802,7/16/2014 20:27:08,,1324460857,7/16/2014 20:26:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],is performed.,N/A,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 20:27:40,,1324461122,7/16/2014 20:27:17,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"concern,",asd,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 20:34:26,,1324463986,7/16/2014 20:33:54,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is performed.,n/a,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 20:50:59,,1324470778,7/16/2014 20:49:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],is performed.,N/A,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 21:00:06,,1324474530,7/16/2014 20:59:34,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"a concern,",Na,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 21:12:54,,1324482455,7/16/2014 21:12:14,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is performed.,N/A,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 21:15:32,,1324483788,7/16/2014 21:15:01,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"TB is a concern, PPD is performed.",n/a,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 21:23:25,,1324487245,7/16/2014 21:22:43,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]","is a concern,",[ASSOCIATED_WITH] [IS_A],3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 21:37:32,,1324493042,7/16/2014 21:36:24,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[PREVENTS],[PREVENTS],performed.,N/A,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 22:27:17,,1324512098,7/16/2014 22:26:55,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],performed.,na,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 22:28:17,,1324512600,7/16/2014 22:27:53,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"is a concern, is performed.",N/A,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 22:34:29,,1324515068,7/16/2014 22:34:16,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],performed.,N/A,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/16/2014 22:59:44,,1324525112,7/16/2014 22:58:47,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"If TB is a concern, PPD is performed.",N/A,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/17/2014 00:40:11,,1324574863,7/17/2014 00:38:25,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"is a concern,",N/A,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544802,7/17/2014 00:51:32,,1324585578,7/17/2014 00:50:49,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is performed.,N/A,3,22,4,25,1,RO-may_diagnose,906829-FS1,"If TB is a concern, a PPD is performed.",TB,PPD
503544803,7/16/2014 20:24:03,,1324459428,7/16/2014 20:23:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],including,N/A,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/16/2014 20:26:20,,1324460454,7/16/2014 20:25:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA,N/A,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/16/2014 20:58:59,,1324473938,7/16/2014 20:56:38,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is caused by,N/A,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/16/2014 21:22:58,,1324487037,7/16/2014 21:21:59,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is caused by CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA,N/A,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/16/2014 22:33:02,,1324514428,7/16/2014 22:32:38,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],is caused by,N/A,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/16/2014 22:41:19,,1324518176,7/16/2014 22:40:44,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[IS_A],[IS_A],including,na,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/16/2014 23:00:38,,1324525383,7/16/2014 23:00:03,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],including,na,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/16/2014 23:11:17,,1324529172,7/16/2014 23:10:23,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[ASSOCIATED_WITH],[ASSOCIATED_WITH],caused by three pathophysiological mechanisms:,n/a,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/16/2014 23:30:48,,1324537836,7/16/2014 23:30:29,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including related,N/A,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/17/2014 01:16:39,,1324609201,7/17/2014 01:16:28,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],including,N/A,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/17/2014 01:31:57,,1324624641,7/17/2014 01:31:21,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[PART_OF],[PART_OF],including,N/A,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/17/2014 01:55:14,,1324647723,7/17/2014 01:53:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],including,n/a,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/17/2014 02:03:13,,1324655787,7/17/2014 02:02:23,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",CLONAL THROMBOCYTOSIS ESSENTIAL THROMBOCYTHEMIA,n/a,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/17/2014 04:20:44,,1324788529,7/17/2014 04:19:43,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544803,7/17/2014 04:21:14,,1324789119,7/17/2014 04:21:02,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,150,182,170,207,1,RO-disease_has_finding,901539-FS1,Thrombocytosis is caused by three major pathophysiological mechanisms: (1) reactive or secondary thrombocytosis; (2) familial thrombocytosis; and (3) CLONAL THROMBOCYTOSIS including ESSENTIAL THROMBOCYTHEMIA and related myeloproliferative disorders.,CLONAL THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503544804,7/16/2014 20:18:38,,1324457082,7/16/2014 20:18:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],in,N/A,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 20:26:16,,1324460422,7/16/2014 20:26:03,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[LOCATION],[LOCATION],MYOCARDIAL ISCHAEMIA in guinea pig HEART:,N/A,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 20:26:23,,1324460478,7/16/2014 20:26:08,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],myocardial HEART:,Na,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 20:34:56,,1324464164,7/16/2014 20:34:28,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],in,N/A,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 20:38:15,,1324465491,7/16/2014 20:37:58,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],in guinea pig HEART:,n/a,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 21:14:01,,1324483082,7/16/2014 21:13:15,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[LOCATION],[LOCATION],in,N/A,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 21:18:17,,1324485207,7/16/2014 21:17:36,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],MYOCARDIAL ISCHAEMIA in guinea pig HEART:,n/a,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 21:20:17,,1324485986,7/16/2014 21:19:40,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were investigated after four conditions of,[DIAGNOSE_BY_TEST_OR_DRUG],143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 21:25:21,,1324488181,7/16/2014 21:24:17,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],in,N/A,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 22:39:21,,1324517344,7/16/2014 22:38:42,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],four conditions of in guinea pig HEART:,N/A,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 23:05:01,,1324527000,7/16/2014 23:04:32,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[LOCATION],[LOCATION],in guinea pig,n/a,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 23:06:16,,1324527431,7/16/2014 23:05:37,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[LOCATION],[LOCATION],in,n/a,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 23:14:14,,1324530296,7/16/2014 23:13:23,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[LOCATION],[LOCATION],conditions of MYOCARDIAL ISCHAEMIA in HEART:,N/A,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/16/2014 23:28:18,,1324536901,7/16/2014 23:26:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[LOCATION],[LOCATION],in,N/A,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544804,7/17/2014 01:26:50,,1324619042,7/17/2014 01:26:13,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated,not applicable,143,108,147,128,1,RO-has_finding_site,905220-FS1,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
503544805,7/16/2014 20:21:55,,1324458503,7/16/2014 20:21:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],effects on,N/A,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 20:39:32,,1324466077,7/16/2014 20:39:11,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"osteoporosis susceptibility,",asd,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 20:40:33,,1324466499,7/16/2014 20:40:12,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],in the pathogenesis of,N/A,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 20:40:41,,1324466552,7/16/2014 20:38:42,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,Both are affected by the same thing but not related to each other.,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 20:42:37,,1324467278,7/16/2014 20:42:16,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[SYMPTOM],[SYMPTOM],"osteoporosis susceptibility,",Na,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 20:49:09,,1324470050,7/16/2014 20:48:41,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[CAUSES],[CAUSES],osteoporosis,NONE,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 20:52:25,,1324471377,7/16/2014 20:52:09,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[CAUSES],[CAUSES],implicated in the pathogenesis,n/a,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 21:04:50,,1324477221,7/16/2014 21:04:04,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",has been implicated in,N/A,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 21:06:57,,1324478477,7/16/2014 21:06:36,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[LOCATION],[LOCATION],on,N/A,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 21:19:50,,1324485775,7/16/2014 21:18:58,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[LOCATION],[LOCATION],implicated in,n/a,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 21:29:35,,1324490056,7/16/2014 21:28:38,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES],[CAUSES],has been implicated in,[CAUSES],112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 22:34:57,,1324515294,7/16/2014 22:34:45,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],BONE CELLS,N/A,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 22:43:41,,1324518877,7/16/2014 22:43:10,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[LOCATION],[LOCATION],effects on,na,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 23:12:01,,1324529426,7/16/2014 23:11:37,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],BONE CELLS has implicated of OSTEOPOROSIS,N/A,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544805,7/16/2014 23:15:40,,1324530864,7/16/2014 23:14:46,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated items,112,170,121,182,1,RO-disease_has_primary_anatomic_site,902076-FS1,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
503544806,7/16/2014 20:54:27,,1324472160,7/16/2014 20:53:43,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,N/A,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/16/2014 21:26:09,,1324488541,7/16/2014 21:25:19,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALLERGIC RHINITIS FAMILY ATOPY were found,n/a,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/16/2014 21:59:12,,1324501457,7/16/2014 21:58:33,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,separate conditions,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/16/2014 22:24:06,,1324510750,7/16/2014 22:23:54,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/16/2014 23:06:29,,1324527486,7/16/2014 23:06:02,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALLERGIC RHINITIS and FAMILY ATOPY,N/A,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/16/2014 23:13:25,,1324530034,7/16/2014 23:12:46,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/16/2014 23:33:52,,1324539211,7/16/2014 23:32:18,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/17/2014 00:24:27,,1324561400,7/17/2014 00:24:03,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/17/2014 00:33:49,,1324569025,7/17/2014 00:32:09,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/17/2014 01:04:07,,1324597737,7/17/2014 01:03:36,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY,N/A,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/17/2014 01:16:04,,1324608648,7/17/2014 01:15:56,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],ALLERGIC,N/A,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/17/2014 01:21:39,,1324613688,7/17/2014 01:21:20,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY,n/a,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/17/2014 01:53:45,,1324646272,7/17/2014 01:53:22,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],and,similar conditions,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/17/2014 02:00:50,,1324653442,7/17/2014 01:59:56,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALLERGIC RHINITIS FAMILY ATOPY,n/a,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544806,7/17/2014 04:18:52,,1324786908,7/17/2014 04:18:40,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,178,220,194,232,-1,RO-cause_of,900052-FS1,"The prevalences of current asthma, cumulative asthma and asthma like symptoms were found in 1.2, 1.0 and 25.0%, respectively, of the 20 44 years age group and the prevalences of ALLERGIC RHINITIS allergic dermatitis and FAMILY ATOPY were found in 14.5, 10.9, and 15.2%, respectively, in all age group.",ALLERGIC RHINITIS,FAMILY ATOPY
503544807,7/16/2014 20:25:41,,1324460177,7/16/2014 20:25:28,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID,N/A,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 20:29:10,,1324461827,7/16/2014 20:28:53,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PREVENTS],[PREVENTS],prevention of by,N/A,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 20:33:17,,1324463524,7/16/2014 20:32:57,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[PREVENTS],[PREVENTS],prevention of by,N/A,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 20:41:21,,1324466813,7/16/2014 20:40:42,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],prevention by,n/a,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 21:04:04,,1324476854,7/16/2014 21:03:17,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],was discovered by,N/A,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 21:19:38,,1324485685,7/16/2014 21:19:09,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[PREVENTS],[PREVENTS],prevention of,[PREVENTS],189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 21:58:30,,1324501200,7/16/2014 21:57:44,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[PREVENTS],[PREVENTS],prevention of by,na,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 22:32:38,,1324514296,7/16/2014 22:32:27,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[PREVENTS],[PREVENTS],prevention,N/A,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 22:35:08,,1324515421,7/16/2014 22:34:35,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[PREVENTS],[PREVENTS],prevention of,na,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 23:35:16,,1324539851,7/16/2014 23:35:01,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[PREVENTS],[PREVENTS],prevention of by,N/A,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/16/2014 23:58:05,,1324548916,7/16/2014 23:57:14,gifthulk,1.0,21916793,GBR,"","",87.115.178.12,[TREATS],[TREATS],prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID,N/A,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/17/2014 01:11:25,,1324604488,7/17/2014 01:10:32,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PREVENTS],[PREVENTS],prevention of,n/a,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/17/2014 01:30:02,,1324622600,7/17/2014 01:29:34,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[TREATS],[TREATS],prevention of MYOCARDIAL INFARCTION,N/A,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/17/2014 01:48:47,,1324641256,7/17/2014 01:47:36,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MYOCARDIAL INFARCTION ACETYLSALICYLIC ACID,n/a,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544807,7/17/2014 01:54:04,,1324646611,7/17/2014 01:53:03,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[PREVENTS],[PREVENTS],prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID,N/A,189,214,209,234,1,RO-may_prevent,907247-FS1,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID
503544808,7/16/2014 20:24:24,,1324459604,7/16/2014 20:24:16,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/16/2014 20:59:18,,1324474074,7/16/2014 20:57:22,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[CAUSES],[CAUSES],CERVIX,NONE,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/16/2014 21:21:58,,1324486608,7/16/2014 21:20:59,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[LOCATION],[LOCATION],infection of the UTERINE CERVIX CANCER OF THE CERVIX,N/A,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/16/2014 21:51:12,,1324498429,7/16/2014 21:50:42,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[LOCATION],[LOCATION],OF THE CERVIX,na,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/16/2014 23:12:00,,1324529438,7/16/2014 23:11:33,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",causally associated,n/a,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/16/2014 23:16:50,,1324531324,7/16/2014 23:14:56,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/16/2014 23:57:12,,1324548535,7/16/2014 23:56:53,gifthulk,1.0,21916793,GBR,"","",87.115.178.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Persistent infection of the UTERINE CERVIX is causally associated with CANCER OF THE CERVIX,N/A,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/17/2014 01:15:21,,1324607887,7/17/2014 01:15:15,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],CERVIX,N/A,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/17/2014 01:17:03,,1324609570,7/17/2014 01:16:39,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[CAUSES],[CAUSES],Persistent infection,n/a,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/17/2014 01:54:59,,1324647477,7/17/2014 01:54:04,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],UTERINE CERVIX CANCER OF THE CERVIX,n/a,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/17/2014 01:55:20,,1324647812,7/17/2014 01:54:32,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],UTERINE CERVIX CANCER OF THE CERVIX,n/a,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/17/2014 04:12:58,,1324781940,7/17/2014 04:11:47,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[LOCATION],[LOCATION],infection of the UTERINE CERVIX,N/a,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/17/2014 04:18:16,,1324786313,7/17/2014 04:16:54,elite,1.0,27788262,USA,"","",172.129.33.133,[SYMPTOM],[SYMPTOM],is causally associated with,N/A,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/17/2014 05:30:24,,1324851221,7/17/2014 05:28:52,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[ASSOCIATED_WITH] [MANIFESTATION] [LOCATION],"[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]",causally associated,N/A,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544808,7/17/2014 05:33:03,,1324853043,7/17/2014 05:32:41,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,28,115,41,135,1,RO-disease_has_primary_anatomic_site,902354-FS1,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX
503544809,7/16/2014 20:21:34,,1324458364,7/16/2014 20:21:07,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptoms compatible with,n/a,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/16/2014 20:25:06,,1324459913,7/16/2014 20:24:43,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],symptoms,N/A,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/16/2014 20:31:23,,1324462810,7/16/2014 20:31:02,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptoms compatible with,N/A,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/16/2014 20:35:02,,1324464218,7/16/2014 20:34:41,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],CHOLECYSTITIS,asd,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/16/2014 21:18:11,,1324485149,7/16/2014 21:17:29,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[SYMPTOM],[SYMPTOM],must consider,N/A,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/16/2014 21:27:36,,1324489168,7/16/2014 21:25:58,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[OTHER],[OTHER],symptoms compatible with,n/a,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/16/2014 21:54:10,,1324499672,7/16/2014 21:53:30,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",GALLBLADDER METASTASIS presenting symptoms CHOLECYSTITIS,N/A,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/17/2014 01:16:27,,1324608989,7/17/2014 01:16:14,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],symptoms,N/A,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/17/2014 02:02:19,,1324654902,7/17/2014 02:01:40,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[SYMPTOM],[SYMPTOM],GALLBLADDER METASTASIS CHOLECYSTITIS,n/a,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/17/2014 04:16:37,,1324784883,7/17/2014 04:15:36,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[SYMPTOM],[SYMPTOM],presenting with symptoms compatible,N/a,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/17/2014 04:31:10,,1324798298,7/17/2014 04:29:55,elite,1.0,27788262,USA,"","",172.129.33.133,[CAUSES],[CAUSES],presenting with symptoms compatible with,N/A,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/17/2014 05:13:17,,1324836794,7/17/2014 05:12:31,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],symptoms compatible with,N/A,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/17/2014 05:39:00,,1324857855,7/17/2014 05:38:07,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[SYMPTOM],[SYMPTOM],symptoms,because it refers to symptoms,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/17/2014 05:41:25,,1324859681,7/17/2014 05:40:54,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],presenting with symptoms compatible with CHOLECYSTITIS,N/A,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544809,7/17/2014 06:41:51,,1324911591,7/17/2014 06:41:06,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],symptoms,na,102,187,123,200,1,RO-has_finding_site,905346-FS1,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS
503544810,7/16/2014 20:21:16,,1324458206,7/16/2014 20:21:02,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],in the,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 20:24:16,,1324459545,7/16/2014 20:24:04,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],vulnerable,Na,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 20:27:17,,1324460971,7/16/2014 20:25:55,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],in the,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 20:27:24,,1324460993,7/16/2014 20:26:43,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],in the BRAIN,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 20:32:40,,1324463332,7/16/2014 20:31:43,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],BRAIN CEREBRAL,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 20:33:02,,1324463449,7/16/2014 20:32:41,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],function of BRAIN selectively vulnerable during CEREBRAL ISCHEMIA,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 20:49:45,,1324470331,7/16/2014 20:49:03,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],indicate in,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 20:56:45,,1324472993,7/16/2014 20:56:17,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[LOCATION],[LOCATION],inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 21:26:37,,1324488762,7/16/2014 21:26:06,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES],[CAUSES],is selectively vulnerable during,[CAUSES],71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 21:30:26,,1324490311,7/16/2014 21:29:41,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],BRAIN selectively vulnerable CEREBRAL ISCHEMIA,n/a,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 21:49:32,,1324497773,7/16/2014 21:49:22,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],during,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 22:40:14,,1324517743,7/16/2014 22:39:44,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],system in the BRAIN vulnerable during,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 22:57:45,,1324524496,7/16/2014 22:57:07,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[LOCATION],[LOCATION],BRAIN is vulnerable during CEREBRAL ISCHEMIA,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/16/2014 23:39:32,,1324541779,7/16/2014 23:38:20,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SYMPTOM],[SYMPTOM],selectively vulnerable,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544810,7/17/2014 01:13:14,,1324606196,7/17/2014 01:13:08,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],BRAIN,N/A,71,110,75,127,1,RO-disease_has_primary_anatomic_site,902113-FS1,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
503544811,7/16/2014 20:21:56,,1324458504,7/16/2014 20:21:36,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TESTING,n/a,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 20:29:20,,1324461932,7/16/2014 20:29:03,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],and in reactions to TUBERCULIN TESTING,N/A,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 20:31:30,,1324462844,7/16/2014 20:29:34,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],in reactions to TESTING,n/a,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 20:34:32,,1324464001,7/16/2014 20:34:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to determine the,N/A,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 20:40:02,,1324466276,7/16/2014 20:39:36,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],TUBERCULOSIS,asd,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 20:42:55,,1324467360,7/16/2014 20:42:09,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to determine the incidence.,N/A,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 20:55:13,,1324472465,7/16/2014 20:54:28,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tuberculosis and in reactions to TUBERCULIN TESTING,N/A,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 21:06:33,,1324478267,7/16/2014 21:05:35,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to determine,N/A,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 21:27:18,,1324489082,7/16/2014 21:26:42,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],during the year to determine,[DIAGNOSE_BY_TEST_OR_DRUG],216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 21:47:11,,1324496925,7/16/2014 21:46:59,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],determine,N/A,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/16/2014 23:06:02,,1324527369,7/16/2014 23:05:03,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],determine,n/a,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/17/2014 01:00:01,,1324594175,7/17/2014 00:58:56,elite,1.0,25539687,USA,PA,Windber,71.60.170.59,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],determine,na,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/17/2014 01:11:38,,1324604709,7/17/2014 01:11:26,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TESTING during the year to determine,n/a,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/17/2014 01:16:14,,1324608843,7/17/2014 01:16:06,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN TUBERCULOSIS,N/A,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544811,7/17/2014 01:26:18,,1324618445,7/17/2014 01:25:53,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reactions to TUBERCULIN TESTING,N/A,216,160,227,178,1,RO-may_diagnose,906799-FS1,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING
503544812,7/16/2014 20:19:21,,1324457383,7/16/2014 20:18:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],keratosis,N/A,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 20:35:46,,1324464502,7/16/2014 20:34:57,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,UNrelated conditions/terms,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 20:49:41,,1324470318,7/16/2014 20:49:04,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnoses for very superficial,n/a,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 20:57:34,,1324473294,7/16/2014 20:56:46,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,N/A,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 21:05:34,,1324477667,7/16/2014 21:04:52,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],by diagnoses,N/A,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 21:28:19,,1324489441,7/16/2014 21:25:23,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],for very superficial squamous cell carcinoma as disparate as,N/A,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 21:45:00,,1324496021,7/16/2014 21:43:55,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as,N/A,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 21:51:16,,1324498454,7/16/2014 21:48:19,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[NONE],[NONE],"diagnoses for as disparate ACTINIC KERATOSIS, RADIATION KERATOSIS",These are two different diseases,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 22:24:45,,1324510957,7/16/2014 22:24:36,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 22:39:28,,1324517395,7/16/2014 22:38:40,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],by diagnoses,N/A,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 22:57:05,,1324524270,7/16/2014 22:56:20,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],diagnoses for (ACTINIC KERATOSIS RADIATION KERATOSIS,N/A,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/16/2014 23:07:59,,1324528014,7/16/2014 23:07:14,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/17/2014 01:35:39,,1324628281,7/17/2014 01:35:04,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[PART_OF] [OTHER],"[PART_OF]
[OTHER]",KERATOSIS KERATOSIS,N/A,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/17/2014 01:49:58,,1324642459,7/17/2014 01:48:52,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(ACTINIC KERATOSIS RADIATION KERATOSIS,n/a,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544812,7/17/2014 02:03:14,,1324655778,7/17/2014 02:02:21,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(ACTINIC KERATOSIS RADIATION KERATOSIS,n/a,210,152,228,169,-1,RO-disease_has_finding,901786-FS1,"This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous cell carcinoma as disparate as solar keratosis (ACTINIC KERATOSIS senile keratosis), arsenical keratosis, RADIATION KERATOSIS Bowen disease, bowenoid papulosis, squamous cell carcinoma in situ, as well as variations on the theme of keratinocytic intraepidermal neoplasia and dysplasia, and in the cervix by squamous cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I III, as well as variations on the theme of squamous dysplasia ().",RADIATION KERATOSIS,ACTINIC KERATOSIS
503544813,7/16/2014 20:28:18,,1324461450,7/16/2014 20:27:51,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/16/2014 20:34:17,,1324463922,7/16/2014 20:33:54,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/16/2014 21:17:08,,1324484595,7/16/2014 21:16:47,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/16/2014 21:28:02,,1324489316,7/16/2014 21:27:27,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[IS_A],[IS_A],SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III),N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/16/2014 21:45:34,,1324496293,7/16/2014 21:45:24,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[OTHER],[OTHER],or,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/16/2014 21:54:14,,1324499709,7/16/2014 21:53:29,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,separate conditions,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/16/2014 22:20:16,,1324509303,7/16/2014 22:19:24,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",confirmed diagnosis SEVERE DYSPLASIA CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III),n/a,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/16/2014 23:06:40,,1324527573,7/16/2014 23:05:54,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/17/2014 00:14:50,,1324556681,7/17/2014 00:14:22,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],confirmed diagnosis of,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/17/2014 01:15:00,,1324607562,7/17/2014 01:14:49,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/17/2014 01:31:53,,1324624547,7/17/2014 01:29:55,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",confirmed diagnosis SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/17/2014 01:51:58,,1324644551,7/17/2014 01:51:40,bitcoinget,1.0,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis of or,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/17/2014 02:32:33,,1324684491,7/17/2014 02:31:43,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis or,none,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/17/2014 05:30:50,,1324851600,7/17/2014 05:30:19,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],in patients with or,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544813,7/17/2014 05:33:49,,1324853648,7/17/2014 05:32:39,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[OTHER],[OTHER],or,N/A,95,115,110,164,-1,RO-disease_has_finding,901940-FS1,Results of cryosurgical treatment in 102 patients with a histologically confirmed diagnosis of SEVERE DYSPLASIA or CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III) are presented.,SEVERE DYSPLASIA,CARCINOMA IN SITU OF THE UTERINE CERVIX (CIN III)
503544814,7/16/2014 20:27:21,,1324460980,7/16/2014 20:27:02,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"SSPE, SSPE BRAIN TISSUES BRAIN cultures",N/A,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/16/2014 20:28:38,,1324461580,7/16/2014 20:27:37,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],is invariably seen in,n/a,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/16/2014 20:43:52,,1324467723,7/16/2014 20:43:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],"cultures derived from them,",N/A,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/16/2014 21:16:49,,1324484420,7/16/2014 21:14:39,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[PART_OF] [NONE],"[PART_OF]
[NONE]",n/a,SSPE BRAIN TISSUES BRAIN is the brain,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/16/2014 21:41:46,,1324494681,7/16/2014 21:41:33,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],derived from,N/A,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 01:36:00,,1324628718,7/17/2014 01:35:40,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[LOCATION],[LOCATION],BRAIN cultures,N/A,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 02:07:55,,1324660548,7/17/2014 02:06:59,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",SSPE BRAIN TISSUES BRAIN,n/a,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 03:37:48,,1324749342,7/17/2014 03:37:21,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[LOCATION],[LOCATION],seen in,na,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 03:56:02,,1324766461,7/17/2014 03:54:54,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[LOCATION],[LOCATION],invariably seen in SSPE BRAIN TISSUES,N/A,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 04:14:04,,1324782881,7/17/2014 04:13:04,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[PART_OF],[PART_OF],infected with,"Because:

seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.

it is a part of SSPE viruses",205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 04:22:13,,1324790077,7/17/2014 04:21:59,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],seen,N/A,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 04:25:03,,1324792690,7/17/2014 04:22:28,elite,1.0,27788262,USA,"","",172.129.33.133,[OTHER],[OTHER],SSPE BRAIN TISSUES BRAIN,N/A,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 05:15:11,,1324838659,7/17/2014 05:14:19,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],BRAIN BRAIN,N/A,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 05:21:33,,1324844403,7/17/2014 05:21:09,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],BRAIN,n/a,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544814,7/17/2014 05:37:32,,1324856659,7/17/2014 05:36:51,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[LOCATION],[LOCATION],SSPE BRAIN TISSUES BRAIN,N/A,205,200,209,218,1,RO-disease_has_primary_anatomic_site,902239-FS1,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES
503544815,7/16/2014 20:23:21,,1324459193,7/16/2014 20:22:51,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 20:25:49,,1324460207,7/16/2014 20:25:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],and,Na,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 20:28:40,,1324461605,7/16/2014 20:28:16,instagc,1,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],METAPLASIA AND DYSPLASIA and CERVICAL INTRAEPITHELIAL NEOPLASIA,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 20:34:56,,1324464169,7/16/2014 20:33:57,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],pre cancer lesions such as,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 20:36:35,,1324464891,7/16/2014 20:36:14,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],of the lung and,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 21:40:02,,1324494025,7/16/2014 21:39:08,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pre cancer lesions such as,na,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 21:47:39,,1324497083,7/16/2014 21:47:25,tremorgames,1,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 22:34:15,,1324514969,7/16/2014 22:34:06,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 22:34:59,,1324515302,7/16/2014 22:33:43,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[LOCATION],[LOCATION],expressed on human epithelial tumors,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 23:01:59,,1324525858,7/16/2014 23:00:54,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",CFR 1/PAM 1 receptor is expressed on METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/16/2014 23:42:32,,1324542920,7/16/2014 23:41:52,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/17/2014 01:14:37,,1324607319,7/17/2014 01:14:30,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/17/2014 01:14:43,,1324607375,7/17/2014 01:14:10,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,all forms of cancer,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/17/2014 01:27:28,,1324619767,7/17/2014 01:25:18,prodege,1,15532678,USA,NV,Las Vegas,72.193.104.50,[OTHER],[OTHER],such as METAPLASIA AND DYSPLASIA and CERVICAL INTRAEPITHELIAL NEOPLASIA,N/A,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544815,7/17/2014 01:34:26,,1324627048,7/17/2014 01:33:27,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],METAPLASIA AND DYSPLASIA CERVICAL INTRAEPITHELIAL NEOPLASIA,n/a,358,399,381,433,-1,RO-disease_has_finding,901707-FS1,"This CFR 1/PAM 1 receptor is post transcriptionally modified and over expressed on human epithelial tumors and carcinoma pre cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell METAPLASIA AND DYSPLASIA of the lung and CERVICAL INTRAEPITHELIAL NEOPLASIA",METAPLASIA AND DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA
503544816,7/16/2014 20:38:33,,1324465596,7/16/2014 20:38:12,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],in the treatment of,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/16/2014 20:52:22,,1324471342,7/16/2014 20:51:44,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],were evaluated,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/16/2014 21:26:02,,1324488503,7/16/2014 21:25:28,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS],[TREATS],in the treatment of,[TREATS],170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/16/2014 21:42:03,,1324494765,7/16/2014 21:41:46,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treatment,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/16/2014 22:23:37,,1324510562,7/16/2014 22:23:19,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],placebo,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/16/2014 22:25:53,,1324511431,7/16/2014 22:25:30,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],treatment of,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/16/2014 22:59:00,,1324524901,7/16/2014 22:58:40,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],in the treatment of,na,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/16/2014 23:11:41,,1324529309,7/16/2014 23:11:18,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[TREATS],[TREATS],in the treatment,n/a,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/16/2014 23:41:50,,1324542649,7/16/2014 23:41:33,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/17/2014 00:40:58,,1324575724,7/17/2014 00:40:12,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[TREATS],[TREATS],treatment of,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/17/2014 01:26:54,,1324619133,7/17/2014 01:26:20,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[TREATS],[TREATS],treatment,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/17/2014 01:59:47,,1324652334,7/17/2014 01:59:23,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment of,n/a,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/17/2014 03:48:59,,1324759832,7/17/2014 03:48:28,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[TREATS],[TREATS],NAPROXEN treatment OSTEOARTHRITIS,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/17/2014 04:16:07,,1324784407,7/17/2014 04:15:56,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],treatment,N/A,170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544816,7/17/2014 04:27:46,,1324795081,7/17/2014 04:26:52,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,"NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",170,141,194,149,1,RO-may_treat,908100-FS1,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
503544817,7/16/2014 20:25:32,,1324460107,7/16/2014 20:24:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],under conditions,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/16/2014 20:56:16,,1324472775,7/16/2014 20:55:15,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[NONE],[NONE],N/A,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/16/2014 21:16:45,,1324484357,7/16/2014 21:16:12,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[SYMPTOM],[SYMPTOM],under conditions,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/16/2014 21:24:13,,1324487679,7/16/2014 21:23:34,clixsense,1.0,15189335,GBR,H9,London,188.29.165.176,[TREATS],[TREATS],RESPONSES,Na,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/16/2014 22:32:26,,1324514244,7/16/2014 22:32:12,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],models of,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/16/2014 23:02:46,,1324526108,7/16/2014 23:02:15,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,n/a,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/16/2014 23:03:00,,1324526218,7/16/2014 23:02:03,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[ASSOCIATED_WITH],[ASSOCIATED_WITH],propagation of,n/a,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/16/2014 23:16:21,,1324531138,7/16/2014 23:15:38,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under models of EPILEPSY;,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/17/2014 00:27:06,,1324563421,7/17/2014 00:26:26,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[MANIFESTATION],[MANIFESTATION],under conditions of animal models of,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/17/2014 01:20:32,,1324612802,7/17/2014 01:19:58,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURE RESPONSES under conditions of animal models of EPILEPSY;,n/a,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/17/2014 01:22:41,,1324614854,7/17/2014 01:21:53,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],under conditions of animal models of EPILEPSY;,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/17/2014 01:34:17,,1324626836,7/17/2014 01:33:37,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],under conditions,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/17/2014 03:49:38,,1324760411,7/17/2014 03:49:00,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[SYMPTOM] [MANIFESTATION] [SIDE_EFFECT],"[SYMPTOM]
[MANIFESTATION]
[SIDE_EFFECT]",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES EPILEPSY;,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/17/2014 04:17:22,,1324785561,7/17/2014 04:16:38,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],under conditions of,N/a,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544817,7/17/2014 04:20:35,,1324788411,7/17/2014 04:20:23,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],animal models,N/A,116,201,162,209,-1,RO-has_definitional_manifestation,904940-FS1,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY
503544818,7/16/2014 20:24:08,,1324459473,7/16/2014 20:22:35,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],due to variations in the,n/a,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 20:28:33,,1324461549,7/16/2014 20:28:23,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was investigated,N/A,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 20:30:12,,1324462320,7/16/2014 20:29:41,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ANTIGENIC PROPERTIES OF SKIN was investigated by SKIN SPECIFIC PEMPHIGUS VULGARIS,N/A,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 20:30:22,,1324462396,7/16/2014 20:29:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated by,N/A,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 20:32:40,,1324463324,7/16/2014 20:32:14,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[SYMPTOM],[SYMPTOM],PEMPHIGUS VULGARIS,asd,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 20:35:52,,1324464567,7/16/2014 20:35:35,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigated,N/A,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 20:53:07,,1324471651,7/16/2014 20:52:24,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],was investigated,N/A,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 21:25:55,,1324488462,7/16/2014 21:24:27,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",is due to,n/a,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 21:48:14,,1324497274,7/16/2014 21:48:03,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],expression,N/A,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 22:53:00,,1324522485,7/16/2014 22:52:24,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",was investigated by,n/a,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 23:01:05,,1324525545,7/16/2014 22:59:51,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[SYMPTOM],[SYMPTOM],investigated by mapping the expression of,n.a,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/16/2014 23:12:24,,1324529615,7/16/2014 23:11:51,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was investigated by mapping the expression of the,na,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/17/2014 00:19:49,,1324559064,7/17/2014 00:18:17,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[MANIFESTATION],[MANIFESTATION],investigated by mapping the expression,N/A,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/17/2014 00:48:54,,1324583277,7/17/2014 00:46:41,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[SIDE_EFFECT],[SIDE_EFFECT],was investigated by mapping the expression of the,I didn't,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544818,7/17/2014 01:31:02,,1324623553,7/17/2014 01:29:17,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[PART_OF],[PART_OF],mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS,n/a,109,188,136,220,1,RO-disease_has_primary_anatomic_site,902125-FS1,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
503544819,7/16/2014 20:27:44,,1324461140,7/16/2014 20:27:09,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 20:33:45,,1324463715,7/16/2014 20:33:20,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],MALNUTRITION,asd,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 20:47:43,,1324469370,7/16/2014 20:45:39,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 21:09:19,,1324479920,7/16/2014 21:09:06,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 21:21:10,,1324486298,7/16/2014 21:20:18,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES],[CAUSES],affect millions of people,[CAUSES],0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 21:48:20,,1324497315,7/16/2014 21:47:42,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MALNUTRITION and DEFICIENCIES,na,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 22:32:56,,1324514399,7/16/2014 22:32:39,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 22:33:25,,1324514584,7/16/2014 22:33:02,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],and,N/A,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 23:01:01,,1324525502,7/16/2014 23:00:35,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],and,n/a,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 23:18:28,,1324532123,7/16/2014 23:18:04,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",PROTEIN ENERGY MALNUTRITION and DEFICIENCIES,N/A,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/16/2014 23:31:34,,1324538277,7/16/2014 23:31:06,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/17/2014 00:27:50,,1324564145,7/17/2014 00:27:08,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],affect millions of people in developing countries.,N/A,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/17/2014 01:00:38,,1324594734,7/17/2014 00:58:10,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/17/2014 01:17:05,,1324609591,7/17/2014 01:17:01,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544819,7/17/2014 02:27:30,,1324679412,7/17/2014 02:27:06,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,0,32,26,44,-1,RO-cause_of,900464-FS1,"PROTEIN ENERGY MALNUTRITION and DEFICIENCIES of iron, vitamin A and iodine affect millions of people in developing countries.",PROTEIN ENERGY MALNUTRITION,DEFICIENCIES
503544820,7/16/2014 20:27:38,,1324461101,7/16/2014 20:27:22,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],MECONIUM PERITONITIS occurs following BOWEL PERFORATION,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 20:29:34,,1324462021,7/16/2014 20:29:09,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],which occurs following,n/a,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 20:31:17,,1324462760,7/16/2014 20:30:50,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],occurs,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 20:33:20,,1324463529,7/16/2014 20:32:42,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],which occurs following,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 21:01:47,,1324475640,7/16/2014 21:01:37,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[CAUSES],[CAUSES],PERITONITIS,NONE,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 21:08:09,,1324479158,7/16/2014 21:07:52,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[CAUSES],[CAUSES],following,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 21:54:53,,1324499968,7/16/2014 21:54:11,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[CAUSES],[CAUSES],MECONIUM PERITONITIS occurs following BOWEL PERFORATION,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 22:41:30,,1324518208,7/16/2014 22:40:48,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF] [OTHER],"[PART_OF]
[OTHER]",which occurs,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 23:12:43,,1324529730,7/16/2014 23:12:02,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",MECONIUM PERITONITIS which occurs following BOWEL PERFORATION,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 23:17:16,,1324531540,7/16/2014 23:16:27,clixsense,1.0,11338264,CAN,ON,Aurora,184.148.114.225,[CAUSES],[CAUSES],MECONIUM PERITONITIS occurs following BOWEL PERFORATION,N/a,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/16/2014 23:41:32,,1324542535,7/16/2014 23:41:12,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],occurs following,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/17/2014 00:15:27,,1324556893,7/17/2014 00:14:52,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],occurs following,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/17/2014 00:28:10,,1324564392,7/17/2014 00:27:06,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[SYMPTOM],[SYMPTOM],chemical peritonitis occurs following,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/17/2014 00:58:09,,1324592067,7/17/2014 00:57:31,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],which occurs following,N/A,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544820,7/17/2014 00:58:55,,1324592861,7/17/2014 00:56:19,elite,1,25539687,USA,PA,Windber,71.60.170.59,[CAUSES],[CAUSES],following,i did not,0,70,19,87,1,RO-cause_of,900224-FS1,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
503544821,7/16/2014 20:30:29,,1324462474,7/16/2014 20:30:06,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],receiving,N/A,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/16/2014 20:49:01,,1324470007,7/16/2014 20:48:39,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],patients receiving,N/A,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/16/2014 21:11:04,,1324481049,7/16/2014 21:09:40,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[SIDE_EFFECT],[SIDE_EFFECT],to onset,n/a,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/16/2014 21:29:39,,1324490083,7/16/2014 21:28:52,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],time to onset ANGINA 5.7 0.9 minutes with BEPRIDIL,n/a,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/16/2014 21:39:20,,1324493671,7/16/2014 21:38:34,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[MANIFESTATION],[MANIFESTATION],during exercise was 5.7 +/ 0.9 minutes with,[MANIFESTATION],139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/16/2014 21:40:12,,1324494101,7/16/2014 21:39:58,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/16/2014 23:10:03,,1324528702,7/16/2014 23:09:29,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],receiving during exercise was,na,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/16/2014 23:14:56,,1324530556,7/16/2014 23:14:15,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],onset of ANGINA with BEPRIDIL,N/A,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/17/2014 01:24:14,,1324616509,7/17/2014 01:23:40,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[TREATS],[TREATS],placebo,N/A,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/17/2014 01:50:37,,1324643223,7/17/2014 01:49:51,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",receiving bepridil did not experience angina,N/A,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/17/2014 02:28:00,,1324679954,7/17/2014 02:27:30,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[CAUSES],[CAUSES],in,none,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/17/2014 04:20:21,,1324788256,7/17/2014 04:19:46,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],with,N/A,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/17/2014 05:23:09,,1324845854,7/17/2014 05:22:33,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],time to onset of,N/A,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/17/2014 05:35:07,,1324854698,7/17/2014 05:34:06,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],during exercise,"because of:

ANGINA during exercise was 5.7 +/ 0.9 minutes with BEPRIDIL",139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544821,7/17/2014 05:36:50,,1324856119,7/17/2014 05:36:13,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],with,N/A,139,191,144,199,1,RO-may_treat,908351-FS1,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL
503544822,7/16/2014 20:35:51,,1324464558,7/16/2014 20:34:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ARRHYTHMIA ANTIARRHYTHMIC,N/A,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/16/2014 20:51:43,,1324471073,7/16/2014 20:50:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],be based on,N/A,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/16/2014 21:17:35,,1324484836,7/16/2014 21:16:51,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CONTRAINDICATES],[CONTRAINDICATES],ARRHYTHMIA potential side effects ANTIARRHYTHMIC drug.,n/a,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/16/2014 21:23:34,,1324487338,7/16/2014 21:22:43,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[SIDE_EFFECT],[SIDE_EFFECT],side effects,n/a,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/16/2014 21:38:31,,1324493381,7/16/2014 21:37:58,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",treatment must always be based,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/16/2014 21:40:36,,1324494250,7/16/2014 21:40:07,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],drug.,na,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/16/2014 21:42:38,,1324494979,7/16/2014 21:41:19,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[TREATS],[TREATS],antiarrhythmic treatment ARRHYTHMIA ANTIARRHYTHMIC drug.,N/A,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/16/2014 22:33:11,,1324514500,7/16/2014 22:32:57,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],side effects,N/A,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/16/2014 23:35:32,,1324539955,7/16/2014 23:35:17,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/17/2014 00:13:21,,1324556162,7/17/2014 00:12:50,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],choice of the antiarrhythmic treatment,N/A,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/17/2014 01:05:15,,1324598712,7/17/2014 01:04:08,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[SYMPTOM],[SYMPTOM],potential side effects of the,N/A,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/17/2014 01:27:55,,1324620305,7/17/2014 01:27:18,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[TREATS],[TREATS],ANTIARRHYTHMIC drug.,N/A,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/17/2014 01:33:37,,1324626343,7/17/2014 01:32:41,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,n/a,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/17/2014 01:53:02,,1324645552,7/17/2014 01:50:39,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",type of ARRHYTHMIA presence effects the ANTIARRHYTHMIC drug.,N/A,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544822,7/17/2014 01:54:26,,1324646947,7/17/2014 01:53:25,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SIDE_EFFECT],[SIDE_EFFECT],ARRHYTHMIA ANTIARRHYTHMIC,n/a,79,169,88,183,1,RO-may_prevent,907386-FS1,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC
503544823,7/16/2014 20:23:38,,1324459279,7/16/2014 20:23:22,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE,All one term,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/16/2014 20:36:55,,1324465000,7/16/2014 20:36:36,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test.,N/A,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/16/2014 21:38:28,,1324493372,7/16/2014 21:37:39,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[MANIFESTATION],[MANIFESTATION],with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared,NA,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 00:16:14,,1324557153,7/17/2014 00:15:29,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],was cleared completely,N/A,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 00:22:42,,1324560337,7/17/2014 00:19:51,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[NONE],[NONE],there are no words inbetween,there are no words inbetween,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 01:14:28,,1324607247,7/17/2014 01:14:22,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE,N/A,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 02:23:14,,1324675239,7/17/2014 02:22:34,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[PART_OF],[PART_OF],with,none,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 05:26:21,,1324848132,7/17/2014 05:24:41,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[OTHER],[OTHER],CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE,N/A,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 05:28:32,,1324849788,7/17/2014 05:27:18,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],in 75% EXOGENOUS DEXAMETHASONE was cleared completely,N/A,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 05:29:10,,1324850260,7/17/2014 05:28:48,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],cleared,n/a,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 05:36:16,,1324855595,7/17/2014 05:35:09,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[PART_OF],[PART_OF],CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE,"it is one medical expression:

CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE",33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 05:40:17,,1324858810,7/17/2014 05:39:51,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared,N/A,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 06:41:05,,1324910795,7/17/2014 06:40:16,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE,na,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 06:50:45,,1324920197,7/17/2014 06:49:48,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[CAUSES],[CAUSES],was cleared completely,N/a,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544823,7/17/2014 07:17:06,,1324948504,7/17/2014 07:16:15,paiddailysurveys,1.0,11786001,USA,NC,Matthews,71.28.92.249,[CAUSES] [TREATS],"[TREATS]
[CAUSES]",with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE,N/A,33,52,50,75,1,RO-may_diagnose,906695-FS1,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE
503544824,7/16/2014 20:22:27,,1324458796,7/16/2014 20:21:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],showing,N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 20:25:27,,1324460059,7/16/2014 20:25:13,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SEGMENTAL BRONCHI identified BRONCHIECTASIS,N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 20:26:38,,1324460571,7/16/2014 20:26:05,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],correctly identified,N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 20:38:11,,1324465460,7/16/2014 20:37:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"showing bronchiectasis on bronchography, CT correctly identified",N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 21:29:44,,1324490090,7/16/2014 21:28:54,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[LOCATION],[LOCATION],showing,n/a,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 21:31:36,,1324490717,7/16/2014 21:30:21,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],correctly identified,[DIAGNOSE_BY_TEST_OR_DRUG],11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 21:36:07,,1324492556,7/16/2014 21:35:09,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[LOCATION],[LOCATION],Of SEGMENTAL BRONCHI identified BRONCHIECTASIS in,N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 22:30:33,,1324513534,7/16/2014 22:30:04,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[IS_A],[IS_A],correctly identified,N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 22:31:43,,1324513964,7/16/2014 22:30:45,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[MANIFESTATION],[MANIFESTATION],showing bronchiectasis,N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 22:50:11,,1324521281,7/16/2014 22:49:25,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[LOCATION],[LOCATION],"showing on bronchography,",na,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/16/2014 23:02:07,,1324525887,7/16/2014 23:00:39,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/17/2014 00:12:50,,1324555958,7/17/2014 00:12:07,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],showing bronchiectasis,N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/17/2014 00:18:16,,1324558115,7/17/2014 00:16:35,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],showing,I did not select none,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/17/2014 01:02:43,,1324596476,7/17/2014 01:01:27,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[PART_OF],[PART_OF],CT correctly identified,N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544824,7/17/2014 01:29:06,,1324621822,7/17/2014 01:28:41,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[LOCATION],[LOCATION],showing,N/A,11,94,27,108,1,RO-has_finding_site,905364-FS1,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
503544825,7/16/2014 20:24:38,,1324459704,7/16/2014 20:24:09,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],is present,n/a,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 20:28:57,,1324461709,7/16/2014 20:28:40,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PRIMARY HYPERPARATHYROIDISM is present 30% patients with MEN2A.,N/A,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 20:40:58,,1324466657,7/16/2014 20:40:34,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],HYPERPARATHYROIDISM,asd,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 20:42:40,,1324467293,7/16/2014 20:42:19,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is present in,n/a,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 20:50:54,,1324470750,7/16/2014 20:50:09,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reveal,Na,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 21:00:27,,1324474775,7/16/2014 20:59:43,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,N/A,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 21:08:28,,1324479388,7/16/2014 21:08:10,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],present in,N/A,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 21:24:53,,1324487966,7/16/2014 21:24:22,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reveal that,[DIAGNOSE_BY_TEST_OR_DRUG],62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 21:41:29,,1324494584,7/16/2014 21:40:43,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[MANIFESTATION],[MANIFESTATION],reveal present in,na,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 21:47:51,,1324497124,7/16/2014 21:47:40,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 22:34:44,,1324515190,7/16/2014 22:34:30,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studies,N/A,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 22:35:33,,1324515636,7/16/2014 22:35:06,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],is present in approximately,N/A,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 22:56:19,,1324523998,7/16/2014 22:55:42,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",is present in,n/a,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 23:10:22,,1324528793,7/16/2014 23:09:44,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[SYMPTOM],[SYMPTOM],is present in,n/a,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 23:13:02,,1324529874,7/16/2014 23:12:25,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is present in,N/A,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544825,7/16/2014 23:24:49,,1324535466,7/16/2014 23:24:25,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is present in approximately 30% of patients with,N/A,62,139,88,144,1,RO-has_manifestation,906333-FS1,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A
503544826,7/16/2014 20:22:50,,1324458971,7/16/2014 20:21:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and X LINKED INFANTILE SPASMS sharing the common features of,N/A,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/16/2014 20:27:09,,1324460851,7/16/2014 20:26:34,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],sharing the common features of,N/A,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/16/2014 20:32:47,,1324463360,7/16/2014 20:32:28,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],features,N/A,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/16/2014 20:39:08,,1324465897,7/16/2014 20:38:37,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],SEIZURES,asd,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/16/2014 20:47:55,,1324469448,7/16/2014 20:47:32,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],have been identified,N/A,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/16/2014 20:49:02,,1324470008,7/16/2014 20:48:20,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[PART_OF],[PART_OF],sharing the common features of generally intractable,n/a,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/16/2014 22:45:11,,1324519399,7/16/2014 22:44:22,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],have been identified,N/A,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/16/2014 23:10:15,,1324528778,7/16/2014 23:08:09,clixsense,1.0,11338264,CAN,ON,Aurora,184.148.114.225,[CAUSES],[CAUSES],SPASMS common features SEIZURES,N/a,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/16/2014 23:15:38,,1324530844,7/16/2014 23:14:57,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],X LINKED INFANTILE SPASMS sharing features of early SEIZURES,N/A,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/17/2014 01:03:36,,1324597272,7/17/2014 01:02:44,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],sharing the common features of generally intractable,N/A,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/17/2014 01:23:46,,1324616095,7/17/2014 01:23:08,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],sharing,not applicable,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/17/2014 01:30:33,,1324623141,7/17/2014 01:30:03,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[OTHER],[OTHER],sharing,N/A,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/17/2014 01:32:41,,1324625287,7/17/2014 01:31:03,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[MANIFESTATION],[MANIFESTATION],sharing the common features of generally intractable early SEIZURES,n/a,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/17/2014 01:41:17,,1324634049,7/17/2014 01:39:21,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],X LINKED INFANTILE SPASMS SEIZURES,n/a,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544826,7/17/2014 02:23:01,,1324674990,7/17/2014 02:20:04,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],X LINKED INFANTILE SPASMS SEIZURES,n/a,227,142,234,167,-1,RO-has_definitional_manifestation,904552-FS1,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
503544827,7/16/2014 20:24:22,,1324459585,7/16/2014 20:24:04,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],MILK THISTLE CIRRHOSIS,Not clear in this extract,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/16/2014 20:25:35,,1324460128,7/16/2014 20:24:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],Herbals,N/A,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/16/2014 20:34:43,,1324464088,7/16/2014 20:34:26,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],"(hepatitis,",N/A,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/16/2014 20:38:34,,1324465608,7/16/2014 20:38:12,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CONTRAINDICATES],[CONTRAINDICATES],Therapies Hepatitis,asd,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/16/2014 20:48:37,,1324469796,7/16/2014 20:47:56,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],Alternative for,N/A,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/16/2014 21:41:17,,1324494497,7/16/2014 21:40:30,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[TREATS],[TREATS],Therapies for MILK THISTLE CIRRHOSIS,N/A,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/16/2014 23:03:14,,1324526294,7/16/2014 23:02:08,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],Least Evidencec Herbals,na,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/16/2014 23:06:01,,1324527354,7/16/2014 23:05:15,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[IS_A],[IS_A],"MILK THISTLE (hepatitis, CIRRHOSIS",N/A,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/16/2014 23:07:49,,1324527939,7/16/2014 23:07:00,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[NONE],[NONE],n/a,no clear linkage,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/17/2014 00:29:49,,1324565841,7/17/2014 00:29:08,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[PART_OF],[PART_OF],Alternative Therapies for Hepatitis,N/A,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/17/2014 01:14:21,,1324607145,7/17/2014 01:14:12,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],"(hepatitis,",N/A,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/17/2014 01:19:08,,1324611408,7/17/2014 01:18:41,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],Hepatitis Therapy,n/a,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/17/2014 01:23:07,,1324615407,7/17/2014 01:21:46,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,I don't see any words that show a relation.,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/17/2014 01:25:17,,1324617438,7/17/2014 01:23:26,prodege,1.0,15532678,USA,NV,Las Vegas,72.193.104.50,[TREATS],[TREATS],Alternative Therapies,N/A,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544827,7/17/2014 01:35:40,,1324628316,7/17/2014 01:34:31,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MILK THISTLE CIRRHOSIS,n/a,182,157,190,169,1,RO-may_treat,907669-FS1,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
503544828,7/16/2014 20:22:42,,1324458922,7/16/2014 20:22:26,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],pathogenetic,Na,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/16/2014 20:24:15,,1324459546,7/16/2014 20:23:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has been suggested as a possible pathogenetic factor,N/A,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/16/2014 20:27:48,,1324461155,7/16/2014 20:27:10,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],pathogenetic factor in,N/A,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/16/2014 21:20:03,,1324485876,7/16/2014 21:19:26,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],DIABETES pathogenetic factor DIABETIC NEUROPATHY,n/a,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/16/2014 21:28:52,,1324489720,7/16/2014 21:27:39,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",pathogenetic factor,n/a,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/16/2014 21:39:58,,1324494005,7/16/2014 21:39:42,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[MANIFESTATION],[MANIFESTATION],possible,N/A,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/16/2014 22:37:57,,1324516819,7/16/2014 22:37:20,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM] [LOCATION] [MANIFESTATION],"[LOCATION]
[SYMPTOM]
[MANIFESTATION]",has suggested as a possible pathogenetic factor in,N/A,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/16/2014 22:55:41,,1324523674,7/16/2014 22:54:41,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],been suggested as a possible pathogenetic factor in,n/a,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/16/2014 23:40:12,,1324542032,7/16/2014 23:39:56,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[CAUSES],[CAUSES],pathogenetic factor,N/A,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/17/2014 00:50:48,,1324584839,7/17/2014 00:49:55,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has been suggested as a possible pathogenetic factor in,N/A,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/17/2014 01:13:51,,1324606743,7/17/2014 01:13:44,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIABETES DIABETIC,N/A,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/17/2014 01:31:19,,1324623940,7/17/2014 01:30:34,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[PART_OF],[PART_OF],possible pathogenetic factor,N/A,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/17/2014 01:58:07,,1324650616,7/17/2014 01:56:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pathogenetic factor DIABETIC NEUROPATHY,n/a,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/17/2014 02:05:17,,1324657739,7/17/2014 02:04:20,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIABETES DIABETIC NEUROPATHY,n/a,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544828,7/17/2014 04:21:01,,1324788860,7/17/2014 04:20:49,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[CAUSES],[CAUSES],pathogenetic factor,N/A,153,88,171,96,1,RO-cause_of,900234-FS1,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES
503544829,7/16/2014 20:29:02,,1324461758,7/16/2014 20:28:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],is the causative agent,N/A,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 20:29:37,,1324462031,7/16/2014 20:29:22,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],causative agent of,N/A,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 20:53:05,,1324471652,7/16/2014 20:52:28,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE,N/A,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 20:53:43,,1324471863,7/16/2014 20:53:08,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],is causative of,N/A,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 21:00:50,,1324475093,7/16/2014 21:00:16,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[CAUSES],[CAUSES],DISEASE,NONE,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 21:18:37,,1324485320,7/16/2014 21:18:12,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES],[CAUSES],is the causative agent of,[CAUSES],4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 21:22:40,,1324486938,7/16/2014 21:22:08,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[CAUSES],[CAUSES],causative,n/a,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 22:35:05,,1324515383,7/16/2014 22:34:12,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],is the causative agent of,N/A,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 22:47:49,,1324520531,7/16/2014 22:47:30,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],causative agent,N/A,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 22:59:51,,1324525147,7/16/2014 22:59:26,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[CAUSES],[CAUSES],causative agent,n/a,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 23:12:44,,1324529752,7/16/2014 23:12:25,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],is the causative agent of,na,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 23:18:38,,1324532210,7/16/2014 23:17:30,superrewards,1,26561650,NLD,06,Tilburg,84.87.179.65,[CAUSES],[CAUSES],causative of LYME DISEASE,N/A,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/16/2014 23:26:05,,1324535978,7/16/2014 23:25:55,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[CAUSES],[CAUSES],is the causative agent of,N/A,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/17/2014 01:14:58,,1324607535,7/17/2014 01:14:44,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[CAUSES],[CAUSES],causative agent,n/a,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544829,7/17/2014 01:34:32,,1324627101,7/17/2014 01:34:18,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[CAUSES],[CAUSES],causative,N/A,4,62,34,74,1,RO-has_causative_agent,903501-FS1,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
503544830,7/16/2014 20:33:30,,1324463589,7/16/2014 20:33:13,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],require,N/A,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 20:37:46,,1324465306,7/16/2014 20:37:18,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[MANIFESTATION],[MANIFESTATION],TYPE 2 DIABETES,asd,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 20:55:14,,1324472471,7/16/2014 20:54:01,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with,Na,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 21:21:36,,1324486434,7/16/2014 21:21:06,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],TYPE 2 DIABETES eventually require INSULIN THERAPY.,n/a,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 21:34:15,,1324491812,7/16/2014 21:33:38,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[TREATS],[TREATS],require,n/a,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 21:36:10,,1324492563,7/16/2014 21:35:34,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS],[TREATS],eventually require,[TREATS],49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 21:45:03,,1324496039,7/16/2014 21:44:37,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],THERAPY.,na,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 22:28:41,,1324512796,7/16/2014 22:28:18,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],eventually require INSULIN THERAPY.,N/A,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 22:46:11,,1324519824,7/16/2014 22:45:39,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],require,na,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 23:02:13,,1324525950,7/16/2014 23:01:33,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],eventually require,n/a,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 23:08:04,,1324528041,7/16/2014 23:07:41,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[TREATS],[TREATS],eventually require,N/A,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 23:31:04,,1324538019,7/16/2014 23:30:19,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[TREATS],[TREATS],require,n/a,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/16/2014 23:40:32,,1324542133,7/16/2014 23:40:14,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/17/2014 00:18:17,,1324558140,7/17/2014 00:18:04,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],eventually require,N/A,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544830,7/17/2014 01:25:10,,1324617347,7/17/2014 01:24:39,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],eventually require,not applicable,49,84,63,99,1,RO-may_treat,907826-FS1,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY
503544831,7/16/2014 20:21:00,,1324458085,7/16/2014 20:20:36,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic tests for tuberculosis based on,N/A,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/16/2014 20:21:53,,1324458493,7/16/2014 20:21:41,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic tests,Na,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/16/2014 21:22:07,,1324486695,7/16/2014 21:21:21,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic tests,n/a,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/16/2014 21:57:08,,1324500746,7/16/2014 21:56:09,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic tests,na,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/16/2014 22:26:48,,1324511879,7/16/2014 22:25:54,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]","tests have poor specificity, and both BCG vaccination and exposure to non",N/A,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/16/2014 22:32:37,,1324514287,7/16/2014 22:32:08,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic tests,N/A,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/16/2014 23:10:27,,1324528833,7/16/2014 23:09:52,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],exposure,n/a,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/17/2014 01:19:52,,1324612192,7/17/2014 01:18:17,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],TUBERCULIN,n/a,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/17/2014 02:00:21,,1324652939,7/17/2014 01:59:17,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN TUBERCULOSIS,n/a,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/17/2014 02:21:37,,1324673594,7/17/2014 02:21:10,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tests,none,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/17/2014 04:15:36,,1324784018,7/17/2014 04:14:47,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[SYMPTOM],[SYMPTOM],tuberculosis based on TUBERCULIN,N/a,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/17/2014 04:18:52,,1324786899,7/17/2014 04:18:17,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,"TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS",130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/17/2014 05:27:17,,1324848857,7/17/2014 05:26:44,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic tests for,N/A,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/17/2014 05:28:50,,1324850024,7/17/2014 05:27:21,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic tests,N/A,130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544831,7/17/2014 05:30:12,,1324851066,7/17/2014 05:29:15,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Current diagnostic tests,"because of

Current diagnostic tests for tuberculosis based on TUBERCULIN",130,51,141,61,1,RO-may_diagnose,906619-FS1,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN
503544832,7/16/2014 20:24:41,,1324459723,7/16/2014 20:24:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],EYELID hygiene.,N/A,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/16/2014 20:28:10,,1324461381,7/16/2014 20:27:39,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,This extract does not make the relation clear,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/16/2014 20:29:11,,1324461842,7/16/2014 20:28:50,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],BLEPHARITIS,asd,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/16/2014 21:44:31,,1324495804,7/16/2014 21:43:45,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[LOCATION],[LOCATION],that persists despite EYELID hygiene.,na,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/16/2014 22:41:54,,1324518298,7/16/2014 22:40:57,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],sign of DLE,N/A,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/16/2014 23:08:24,,1324528147,7/16/2014 23:07:44,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],medical management,n/a,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/16/2014 23:34:16,,1324539391,7/16/2014 23:33:53,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the absence,N/A,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/17/2014 00:30:56,,1324566572,7/17/2014 00:30:29,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],that persists despite usual medical management,N/A,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/17/2014 01:59:02,,1324651635,7/17/2014 01:58:00,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BLEPHARITIS EYELID,n/a,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/17/2014 02:01:37,,1324654084,7/17/2014 01:59:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],EYELID,n/a,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/17/2014 04:22:46,,1324790561,7/17/2014 04:22:27,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],persists,N/A,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/17/2014 04:28:26,,1324795640,7/17/2014 04:27:48,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,BLEPHARITIS that persists despite usual medical management and EYELID hygiene.,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/17/2014 04:46:13,,1324811881,7/17/2014 04:43:27,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[LOCATION] [MANIFESTATION],"[LOCATION]
[MANIFESTATION]",chronic BLEPHARITIS persists despite EYELID hygiene.,N/A,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/17/2014 05:25:23,,1324847434,7/17/2014 05:24:46,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],usual medical management and,N/A,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544832,7/17/2014 05:38:00,,1324857052,7/17/2014 05:37:33,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[LOCATION],[LOCATION],that persists despite usual medical management and EYELID hygiene.,N/A,257,194,262,205,1,RO-has_finding_site,905409-FS1,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS
503544833,7/16/2014 20:25:56,,1324460277,7/16/2014 20:25:36,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],causative organism,N/A,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/16/2014 20:36:14,,1324464697,7/16/2014 20:35:41,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],(MYCOBACTERIUM LEPRAE,asd,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/16/2014 20:48:11,,1324469592,7/16/2014 20:47:53,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],causative organism,N/A,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/16/2014 21:21:05,,1324486281,7/16/2014 21:20:33,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],LEPROSY causative organism (MYCOBACTERIUM LEPRAE,n/a,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/16/2014 21:28:34,,1324489538,7/16/2014 21:27:49,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[TREATS],[TREATS],its prolonged treatment,[TREATS],68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/16/2014 21:45:23,,1324496217,7/16/2014 21:45:02,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the chronicity,N/A,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/16/2014 21:52:51,,1324499152,7/16/2014 21:52:21,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[CAUSES],[CAUSES],causative organism,na,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/16/2014 22:30:58,,1324513699,7/16/2014 22:30:34,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],causative organism,N/A,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/16/2014 23:08:40,,1324528222,7/16/2014 23:07:50,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[SYMPTOM],[SYMPTOM],causative organism,n/a,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/16/2014 23:11:50,,1324529379,7/16/2014 23:11:17,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],is unique in terms of the nature of the causative organism,na,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/17/2014 01:12:36,,1324605595,7/17/2014 01:12:24,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],(MYCOBACTERIUM,N/A,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/17/2014 01:21:15,,1324613339,7/17/2014 01:19:32,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[PART_OF],[PART_OF],is unique in terms of the nature of the causative organism,N/A,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/17/2014 01:55:48,,1324648293,7/17/2014 01:55:01,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEPROSY (MYCOBACTERIUM LEPRAE,n/a,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/17/2014 02:25:50,,1324677685,7/17/2014 02:25:24,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],is,none,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544833,7/17/2014 03:54:52,,1324765318,7/17/2014 03:52:50,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",causative organism (MYCOBACTERIUM LEPRAE,N/A,68,0,87,7,1,RO-has_causative_agent,903748-FS1,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
503544834,7/16/2014 20:21:05,,1324458124,7/16/2014 20:20:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],responses,Na,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/16/2014 20:24:03,,1324459429,7/16/2014 20:23:40,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],GLUCAGON responses to INSULIN INDUCED HYPOGLYCEMIA,N/A,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/16/2014 20:29:23,,1324461958,7/16/2014 20:29:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],responses to,N/A,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/16/2014 20:59:31,,1324474225,7/16/2014 20:59:04,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[TREATS],[TREATS],responses to,Na,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/16/2014 21:14:22,,1324483270,7/16/2014 21:14:02,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[TREATS],[TREATS],responses,N/A,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/16/2014 21:14:36,,1324483412,7/16/2014 21:12:37,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[SIDE_EFFECT],[SIDE_EFFECT],responses to,n/a,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/16/2014 21:35:32,,1324492316,7/16/2014 21:34:36,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[MANIFESTATION],[MANIFESTATION],norepinephrine responses to,[MANIFESTATION],45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/16/2014 21:43:54,,1324495559,7/16/2014 21:43:40,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],responses,N/A,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/16/2014 23:02:57,,1324526176,7/16/2014 23:02:00,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],GLUCAGON responses to INSULIN INDUCED HYPOGLYCEMIA,N/A,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/16/2014 23:41:10,,1324542380,7/16/2014 23:40:48,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],responses,N/A,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/17/2014 01:24:53,,1324617132,7/17/2014 01:24:15,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],responses,N/A,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/17/2014 01:45:01,,1324637674,7/17/2014 01:43:39,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],responses,n/a,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/17/2014 02:09:00,,1324661603,7/17/2014 02:07:58,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],GLUCAGON INSULIN INDUCED HYPOGLYCEMIA,n/a,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/17/2014 02:18:17,,1324670303,7/17/2014 02:17:42,clixsense,1.0,17548588,CAN,ON,New Hamburg,99.241.226.64,[TREATS],[TREATS],GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA,n/a,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544834,7/17/2014 02:24:17,,1324676171,7/17/2014 02:23:16,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,45,4,72,12,1,RO-may_treat,908243-FS1,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
503544835,7/16/2014 20:25:31,,1324460096,7/16/2014 20:25:08,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],remedy,N/A,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/16/2014 20:35:19,,1324464297,7/16/2014 20:32:04,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[TREATS],[TREATS],remedy,Na,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/16/2014 20:58:39,,1324473775,7/16/2014 20:58:00,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[TREATS],[TREATS],SKIN CONDITIONS including ACTINIC KERATOSIS,N/A,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/16/2014 21:01:34,,1324475532,7/16/2014 21:00:51,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[LOCATION],[LOCATION],CONDITIONS,NONE,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/16/2014 21:14:36,,1324483398,7/16/2014 21:14:23,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[PART_OF],[PART_OF],including,N/A,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/16/2014 22:46:45,,1324520079,7/16/2014 22:46:11,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[IS_A],[IS_A],including,na,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/16/2014 22:55:00,,1324523419,7/16/2014 22:54:39,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[TREATS],[TREATS],is a traditional remedy for,na,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/17/2014 00:22:34,,1324560311,7/17/2014 00:20:49,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[IS_A],[IS_A],including,N/A,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/17/2014 01:19:25,,1324611764,7/17/2014 01:19:09,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],SKIN CONDITIONS including,n/a,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/17/2014 01:37:12,,1324629895,7/17/2014 01:36:46,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[IS_A],[IS_A],SKIN CONDITIONS including ACTINIC KERATOSIS,N/A,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/17/2014 02:11:15,,1324663649,7/17/2014 02:10:01,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SKIN CONDITIONS ACTINIC KERATOSIS,n/a,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/17/2014 02:27:05,,1324678986,7/17/2014 02:26:47,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],remedy,none,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/17/2014 04:13:49,,1324782647,7/17/2014 04:12:58,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SKIN CONDITIONS including ACTINIC KERATOSIS,N/a,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/17/2014 04:19:45,,1324787621,7/17/2014 04:19:34,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],including,N/A,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544835,7/17/2014 04:26:50,,1324794328,7/17/2014 04:25:05,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,SKIN CONDITIONS including ACTINIC KERATOSIS,66,92,80,109,1,RO-disease_has_primary_anatomic_site,902260-FS1,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS
503544836,7/16/2014 20:23:49,,1324459337,7/16/2014 20:23:21,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 20:26:40,,1324460602,7/16/2014 20:25:29,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are separate items in a list.,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 20:29:39,,1324462062,7/16/2014 20:29:14,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,Just a list of unrelated exclusions,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 20:48:38,,1324469811,7/16/2014 20:48:12,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,"two different, unrelated conditions.",73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 20:53:39,,1324471841,7/16/2014 20:53:17,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Differential diagnosis must exclude,n/a,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 21:07:04,,1324478509,7/16/2014 21:06:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis exclude,N/A,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 21:22:39,,1324486932,7/16/2014 21:21:45,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]","nocturnal aspiration, bronchiectasis,",[MANIFESTATION] [SYMPTOM],73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 21:36:35,,1324492736,7/16/2014 21:34:14,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],Differential diagnosis must exclude,N/A,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 21:47:04,,1324496917,7/16/2014 21:46:32,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,separate diseases,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 22:34:03,,1324514882,7/16/2014 22:32:59,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 22:56:55,,1324524197,7/16/2014 22:56:21,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],must exclude an,n/a,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 23:14:45,,1324530495,7/16/2014 23:13:26,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",na,two unrelated items,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/16/2014 23:26:54,,1324536316,7/16/2014 23:26:18,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[NONE],[NONE],n/a,nothing to highlight linkage,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/17/2014 01:15:08,,1324607696,7/17/2014 01:14:45,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",N/A,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544836,7/17/2014 02:17:41,,1324669681,7/17/2014 02:17:09,clixsense,1.0,17548588,CAN,ON,New Hamburg,99.241.226.64,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS",n/a,73,118,78,133,-1,RO-has_manifestation,906342-FS1,"Differential diagnosis must exclude an endobronchial obstructive lesion, ASTHMA nocturnal aspiration, bronchiectasis, CYSTIC FIBROSIS and immotile cilia syndrome.",ASTHMA,CYSTIC FIBROSIS
503544837,7/16/2014 20:25:02,,1324459896,7/16/2014 20:24:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,Na,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/16/2014 20:27:50,,1324461170,7/16/2014 20:27:20,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[PREVENTS],[PREVENTS],prevention,N/A,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/16/2014 20:53:41,,1324471866,7/16/2014 20:53:07,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[TREATS],[TREATS],efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention,N/A,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/16/2014 21:12:13,,1324481912,7/16/2014 21:11:40,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[PREVENTS],[PREVENTS],prevention,N/A,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/16/2014 21:55:20,,1324500142,7/16/2014 21:54:54,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[PREVENTS],[PREVENTS],FLUORIDE SUPPLEMENTS in CARIES prevention,N/A,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/16/2014 22:29:12,,1324512967,7/16/2014 22:28:42,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],efficacy of,na,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/16/2014 22:31:36,,1324513929,7/16/2014 22:30:59,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER] [TREATS],"[TREATS]
[OTHER]",supports the efficacy of,N/A,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/17/2014 01:59:12,,1324651757,7/17/2014 01:58:12,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FLUORIDE SUPPLEMENTS CARIES,n/a,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/17/2014 02:04:16,,1324656766,7/17/2014 02:03:34,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PREVENTS],[PREVENTS],prevention,n/a,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/17/2014 02:29:28,,1324681489,7/17/2014 02:28:59,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],in,none,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/17/2014 04:21:46,,1324789622,7/17/2014 04:21:32,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],efficacy,N/A,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/17/2014 04:37:31,,1324803834,7/17/2014 04:35:21,elite,1.0,27788262,USA,"","",172.129.33.133,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evidence supports the efficacy of FLUORIDE in CARIES,N/A,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/17/2014 05:31:18,,1324851885,7/17/2014 05:30:51,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],the efficacy of prevention,N/A,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/17/2014 05:39:26,,1324858182,7/17/2014 05:39:04,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[OTHER],[OTHER],efficacy of FLUORIDE SUPPLEMENTS in,N/A,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544837,7/17/2014 05:39:58,,1324858607,7/17/2014 05:39:02,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[PREVENTS],[PREVENTS],efficacy of prevention,the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention,73,49,78,69,1,RO-may_prevent,907310-FS1,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS
503544838,7/16/2014 20:43:19,,1324467506,7/16/2014 20:42:56,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],destruction of the,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 20:53:15,,1324471687,7/16/2014 20:52:56,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[TREATS],[TREATS],mediated immune destruction,n/a,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 21:01:37,,1324475545,7/16/2014 21:00:29,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[LOCATION],[LOCATION],HASHIMOTO'S THYROIDITIS THYROID,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 21:29:17,,1324489891,7/16/2014 21:28:21,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],is destruction of the,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 21:41:32,,1324494627,7/16/2014 21:40:29,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],of the,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 22:33:01,,1324514416,7/16/2014 22:32:34,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],is largely cell mediated immune destruction of,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 22:33:40,,1324514705,7/16/2014 22:33:03,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES],[CAUSES],immune destruction,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 22:54:38,,1324523265,7/16/2014 22:52:46,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],largely cell mediated immune destruction of the,na,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 23:03:20,,1324526344,7/16/2014 23:02:48,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[LOCATION],[LOCATION],destruction of the,n/a,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 23:16:44,,1324531297,7/16/2014 23:14:44,superrewards,1.0,26561650,NLD,06,Tilburg,84.87.179.65,[SYMPTOM],[SYMPTOM],destruction of the,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/16/2014 23:30:18,,1324537701,7/16/2014 23:28:31,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[LOCATION] [CAUSES],"[CAUSES]
[LOCATION]",destruction of the,n/a,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/17/2014 00:31:35,,1324567159,7/17/2014 00:30:56,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],destruction of the,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/17/2014 00:49:54,,1324584073,7/17/2014 00:48:55,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[CAUSES],[CAUSES],is largely cell mediated immune destruction of the,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/17/2014 01:12:53,,1324605915,7/17/2014 01:12:24,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],mediated immune destruction,n/a,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544838,7/17/2014 01:23:40,,1324616009,7/17/2014 01:23:14,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[LOCATION],[LOCATION],of the THYROID,N/A,28,16,34,39,1,RO-disease_has_primary_anatomic_site,902140-FS1,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
503544839,7/16/2014 20:54:31,,1324472172,7/16/2014 20:52:11,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SYNDROME,NONE,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/16/2014 21:14:12,,1324483184,7/16/2014 21:13:28,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],WOLFRAM SYNDROME should be considered UNEXPLAINED OPTIC ATROPHY,n/a,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/16/2014 21:37:05,,1324492913,7/16/2014 21:36:12,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],it should be considered in,[DIAGNOSE_BY_TEST_OR_DRUG],89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/16/2014 22:30:02,,1324513307,7/16/2014 22:28:15,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],considered in diabetic patients,N/A,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/16/2014 23:00:14,,1324525313,7/16/2014 22:59:44,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],WOLFRAM SYNDROME be considered in UNEXPLAINED OPTIC ATROPHY,N/A,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/16/2014 23:08:25,,1324528151,7/16/2014 23:08:05,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[ASSOCIATED_WITH],[ASSOCIATED_WITH],should be considered in diabetic patients with,N/A,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/16/2014 23:28:29,,1324537029,7/16/2014 23:26:55,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[ASSOCIATED_WITH],[ASSOCIATED_WITH],should be considered,n/a,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/17/2014 02:33:04,,1324685197,7/17/2014 02:32:34,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[CAUSES],[CAUSES],with,none,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/17/2014 03:55:41,,1324766084,7/17/2014 03:53:43,clixsense,1.0,6416927,USA,CA,San Francisco,107.130.18.82,[MANIFESTATION],[MANIFESTATION],considered,N?A,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/17/2014 04:19:18,,1324787263,7/17/2014 04:18:35,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[SYMPTOM],[SYMPTOM],should be considered in diabetic patients,N/a,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/17/2014 04:33:38,,1324800628,7/17/2014 04:31:52,elite,1.0,27788262,USA,"","",172.129.33.133,[MANIFESTATION],[MANIFESTATION],it should be considered in diabetic patients with,N/A,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/17/2014 05:22:32,,1324845301,7/17/2014 05:22:01,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],it should be considered in diabetic patients with,N/A,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/17/2014 05:32:38,,1324852762,7/17/2014 05:31:39,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",considered,N/A,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/17/2014 05:34:05,,1324853866,7/17/2014 05:33:18,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[SYMPTOM],[SYMPTOM],it should be considered in diabetic patients,"because of the following part in the sentence:

Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY",89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544839,7/17/2014 05:39:50,,1324858501,7/17/2014 05:39:28,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[SYMPTOM],[SYMPTOM],should be considered,N/A,89,13,113,29,1,RO-has_manifestation,906228-FS1,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME
503544840,7/16/2014 20:23:42,,1324459298,7/16/2014 20:23:31,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],is defined as,N/A,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 20:26:43,,1324460612,7/16/2014 20:26:25,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],defined,Na,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 20:27:13,,1324460919,7/16/2014 20:26:46,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],gastrointestinal tract,asd,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 20:28:55,,1324461702,7/16/2014 20:28:41,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],is defined as,N/A,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 20:31:12,,1324462714,7/16/2014 20:30:45,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],in the gastrointestinal tract is defined as,N/A,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 21:11:09,,1324481093,7/16/2014 21:10:28,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[PART_OF],[PART_OF],is defined,N/A,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 21:28:41,,1324489625,7/16/2014 21:28:19,clixsense,1.0,15189335,GBR,H9,London,188.29.165.176,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",defined as,Na,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 21:37:12,,1324492933,7/16/2014 21:36:08,prodege,1,12426026,USA,TX,Trinity,173.184.85.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is defined as,n/a,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 22:27:52,,1324512408,7/16/2014 22:27:25,neodev,1,12115558,USA,OH,Twinsburg,75.187.196.41,[IS_A],[IS_A],is defined as,N/A,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 22:36:10,,1324515961,7/16/2014 22:35:47,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],defined as,N/A,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 23:05:03,,1324527014,7/16/2014 23:04:34,zoombucks,1,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],is defined as,na,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/16/2014 23:12:25,,1324529639,7/16/2014 23:11:43,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,[OTHER],[OTHER],is defined,n/a,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/17/2014 00:30:29,,1324566340,7/17/2014 00:29:50,elite,1,28466071,CAN,AB,Edmonton,68.150.39.46,[IS_A],[IS_A],is defined as,N/A,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/17/2014 01:17:46,,1324610240,7/17/2014 01:17:27,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],defined,N/A,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544840,7/17/2014 01:58:07,,1324650654,7/17/2014 01:56:48,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DYSPLASIA INTRAEPITHELIAL NEOPLASIA,n/a,0,54,8,79,-1,RO-disease_has_finding,901698-FS1,DYSPLASIA in the gastrointestinal tract is defined as INTRAEPITHELIAL NEOPLASIA (IEN) according to the WHO nomenclature.,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA
503544841,7/16/2014 20:33:16,,1324463522,7/16/2014 20:32:43,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MUCOUS AND CUTANEOUS INVOLVEMENT,asd,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/16/2014 20:33:54,,1324463773,7/16/2014 20:33:36,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],severe disease of,N/A,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/16/2014 20:51:40,,1324471053,7/16/2014 20:51:20,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[SYMPTOM],[SYMPTOM],severe disease of,n/a,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/16/2014 21:18:10,,1324485141,7/16/2014 21:17:37,elite,1,28276268,USA,TX,Houston,70.140.36.33,[IS_A],[IS_A],is a,[IS_A],63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/16/2014 21:31:45,,1324490761,7/16/2014 21:29:18,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM],[SYMPTOM],is a disease of both,N/A,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/16/2014 21:35:09,,1324492130,7/16/2014 21:33:43,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",DPA INDUCED CICATRICIAL PEMPHIGOID of MUCOUS AND CUTANEOUS INVOLVEMENT,N/A,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/16/2014 21:43:41,,1324495477,7/16/2014 21:42:40,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[IS_A],[IS_A],is a severe disease of both,na,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/16/2014 22:34:11,,1324514941,7/16/2014 22:33:26,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION] [MANIFESTATION],"[LOCATION]
[MANIFESTATION]",is a severe disease INVOLVEMENT,N/A,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/17/2014 00:19:50,,1324559065,7/17/2014 00:18:16,clixsense,1,21418111,CAN,ON,Guelph,99.225.13.106,[SYMPTOM],[SYMPTOM],severe disease,I did not select none,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/17/2014 00:24:02,,1324561131,7/17/2014 00:23:06,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],is a severe disease of,N/A,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/17/2014 02:25:23,,1324677196,7/17/2014 02:24:59,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],is,none,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/17/2014 04:19:42,,1324787584,7/17/2014 04:18:54,elite,1.0,27788262,USA,"","",172.129.33.133,[IS_A],[IS_A],is a severe disease of both,N/A,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/17/2014 04:23:12,,1324790980,7/17/2014 04:22:58,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[IS_A],[IS_A],is a,N/A,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/17/2014 05:13:56,,1324837527,7/17/2014 05:13:18,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],INVOLVEMENT,N/A,63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544841,7/17/2014 05:31:26,,1324851937,7/17/2014 05:30:14,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[IS_A],[IS_A],is a,"because of:

DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT",63,0,94,34,1,RO-disease_has_finding,901974-FS1,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
503544842,7/16/2014 20:22:14,,1324458656,7/16/2014 20:21:56,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],resulting in,n/a,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 20:23:46,,1324459333,7/16/2014 20:23:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],resulting,Na,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 20:28:51,,1324461693,7/16/2014 20:28:36,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],resulting in,N/A,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 20:32:01,,1324463039,7/16/2014 20:30:20,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[ASSOCIATED_WITH],[ASSOCIATED_WITH],autosomal dominant,Na,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 20:34:12,,1324463898,7/16/2014 20:33:48,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],PROGRESSIVE OSSIFICATION,asd,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 21:16:08,,1324484061,7/16/2014 21:15:34,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],MYOSITIS OSSIFICANS PROGRESSIVA resulting in PROGRESSIVE OSSIFICATION,n/a,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 21:53:29,,1324499382,7/16/2014 21:52:47,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[CAUSES],[CAUSES],MYOSITIS OSSIFICANS PROGRESSIVA resulting in PROGRESSIVE OSSIFICATION,N/A,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 23:04:31,,1324526785,7/16/2014 23:03:54,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],resulting in,n/a,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 23:07:40,,1324527847,7/16/2014 23:07:12,zoombucks,1,4688131,CAN,BC,Vancouver,108.180.143.28,[CAUSES],[CAUSES],resulting in,N/A,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 23:09:43,,1324528581,7/16/2014 23:08:42,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[CAUSES],[CAUSES],resulting in,n/a,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/16/2014 23:11:16,,1324529150,7/16/2014 23:10:48,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],is an autosomal dominant disease resulting in,na,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/17/2014 01:53:20,,1324645881,7/17/2014 01:52:22,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],MYOSITIS OSSIFICANS PROGRESSIVA PROGRESSIVE OSSIFICATION,n/a,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/17/2014 02:31:42,,1324683741,7/17/2014 02:31:23,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[CAUSES],[CAUSES],resulting,none,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/17/2014 05:24:40,,1324846781,7/17/2014 05:23:09,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[CAUSES],[CAUSES],resulting in,NA,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544842,7/17/2014 05:32:40,,1324852759,7/17/2014 05:31:58,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],resulting in,N/A,78,0,101,31,1,RO-disease_has_finding,901735-FS1,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA
503544843,7/16/2014 20:32:56,,1324463431,7/16/2014 20:32:20,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],increased effectiveness almost 4 times more,N/A,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/16/2014 20:52:53,,1324471593,7/16/2014 20:52:27,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"other studies by the same team,",n/a,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/16/2014 21:07:14,,1324478646,7/16/2014 21:06:59,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[TREATS],[TREATS],addition of,N/A,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/16/2014 21:32:27,,1324491050,7/16/2014 21:31:39,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",the addition of,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/16/2014 21:54:47,,1324499945,7/16/2014 21:54:19,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[TREATS],[TREATS],increased effectiveness,na,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/16/2014 22:25:25,,1324511201,7/16/2014 22:25:04,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],40 mg/d,N/A,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/16/2014 22:30:04,,1324513336,7/16/2014 22:29:27,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[TREATS],[TREATS],the addition of EZETIMIBE to 40 mg/d,N/A,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/16/2014 23:09:05,,1324528348,7/16/2014 23:08:26,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],addition increased effectiveness,n/a,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/16/2014 23:24:36,,1324535364,7/16/2014 23:22:34,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[TREATS],[TREATS],increased effectiveness,n/a,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/17/2014 00:25:54,,1324562435,7/17/2014 00:25:12,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],the addition increased effectiveness,N/A,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/17/2014 00:43:31,,1324578210,7/17/2014 00:40:59,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",addition of,n/a,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/17/2014 01:12:07,,1324605164,7/17/2014 01:11:40,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],increased effectiveness,n/a,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/17/2014 01:23:27,,1324615671,7/17/2014 01:22:42,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[OTHER],[OTHER],the addition of,N/A,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/17/2014 01:26:12,,1324618311,7/17/2014 01:25:11,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],increased effectiveness,not applicable,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544843,7/17/2014 01:51:05,,1324643683,7/17/2014 01:50:03,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA EZETIMIBE,n/a,52,109,91,118,1,RO-may_treat,907719-FS1,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
503544844,7/16/2014 20:24:47,,1324459757,7/16/2014 20:24:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],other,Na,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 20:28:23,,1324461494,7/16/2014 20:28:12,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],ALLERGIC RHINITIS and other ATOPIC DISEASES.,N/A,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 20:30:02,,1324462236,7/16/2014 20:29:41,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CAUSES],[CAUSES],ATOPIC DISEASES.,asd,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 20:34:26,,1324463978,7/16/2014 20:34:07,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],other,N/A,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 20:51:18,,1324470927,7/16/2014 20:50:52,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and other,n/a,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 21:07:30,,1324478794,7/16/2014 21:07:15,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and other,N/A,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 21:19:07,,1324485483,7/16/2014 21:18:39,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"asthma, and other",[ASSOCIATED_WITH],172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 21:20:09,,1324485941,7/16/2014 21:19:27,clixsense,1.0,15189335,GBR,H9,London,188.29.165.176,[TREATS],[TREATS],suitable for,Na,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 21:32:40,,1324491140,7/16/2014 21:31:49,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALLERGIC RHINITIS ATOPIC DISEASES.,n/a,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 21:53:25,,1324499332,7/16/2014 21:52:55,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[IS_A],[IS_A],and other,na,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/16/2014 22:56:16,,1324523965,7/16/2014 22:55:38,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[IS_A],[IS_A],"asthma, and other",na,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/17/2014 00:10:55,,1324555243,7/17/2014 00:09:43,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[IS_A],[IS_A],and other,N/A,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/17/2014 01:21:19,,1324613425,7/17/2014 01:21:04,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",n/a,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/17/2014 01:47:31,,1324639967,7/17/2014 01:46:33,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALLERGIC RHINITIS ATOPIC DISEASES.,n/a,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544844,7/17/2014 02:22:02,,1324674014,7/17/2014 02:21:38,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[OTHER],[OTHER],other,none,172,208,188,223,-1,RO-cause_of,900405-FS1,"Pharmacologic agents of this type may be suitable for use in the therapeutic or prophylactic suppression of IgE and, hence, in the therapy of IgE mediated diseases such as ALLERGIC RHINITIS asthma, and other ATOPIC DISEASES.",ALLERGIC RHINITIS,ATOPIC DISEASES
503544845,7/16/2014 20:25:18,,1324459996,7/16/2014 20:25:03,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],epidemiology,Na,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/16/2014 20:29:39,,1324462051,7/16/2014 20:29:15,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],POLIOVIRUS,asd,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/16/2014 21:24:19,,1324487697,7/16/2014 21:23:28,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",evolution has important implications for the epidemiology of,[CAUSES] [MANIFESTATION],39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/16/2014 21:49:10,,1324497651,7/16/2014 21:48:56,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],implications,N/A,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/16/2014 23:04:11,,1324526692,7/16/2014 23:03:41,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[ASSOCIATED_WITH],[ASSOCIATED_WITH],important implications,n/a,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/16/2014 23:04:33,,1324526790,7/16/2014 23:03:16,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated terms,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/16/2014 23:25:09,,1324535611,7/16/2014 23:24:51,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has important implications for the epidemiology of,N/A,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/17/2014 01:06:38,,1324600130,7/17/2014 01:05:36,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[CAUSES],[CAUSES],has important implications,N/A,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/17/2014 01:15:33,,1324608122,7/17/2014 01:14:59,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],important implications for the epidemiology,n/a,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/17/2014 01:32:22,,1324624952,7/17/2014 01:31:58,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[PART_OF],[PART_OF],epidemiology,N/A,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/17/2014 01:32:27,,1324624996,7/17/2014 01:31:43,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],POLIOVIRUS POLIOMYELITIS,n/a,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/17/2014 04:13:53,,1324782676,7/17/2014 04:12:53,elite,1.0,27788262,USA,"","",172.129.33.133,[MANIFESTATION],[MANIFESTATION],has important implications for,N/A,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/17/2014 04:23:03,,1324790814,7/17/2014 04:22:39,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has important implications for,N/a,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/17/2014 05:20:31,,1324843569,7/17/2014 05:19:33,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],evolution has important implications for,N/A,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544845,7/17/2014 05:21:08,,1324844111,7/17/2014 05:20:46,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],epidemiology of POLIOMYELITIS,n/a,39,111,48,124,1,RO-has_causative_agent,903918-FS1,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS
503544846,7/16/2014 21:37:56,,1324493173,7/16/2014 21:37:09,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],has been used as an out patient procedure to assess,[DIAGNOSE_BY_TEST_OR_DRUG],82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/16/2014 21:46:42,,1324496753,7/16/2014 21:46:30,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assess,N/A,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/16/2014 21:56:03,,1324500355,7/16/2014 21:55:37,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assess,na,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/16/2014 22:48:17,,1324520669,7/16/2014 22:47:34,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to assess,na,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/16/2014 23:09:38,,1324528557,7/16/2014 23:09:08,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRACORPOREAL PAPAVERINE assess the ERECTILE DYSFUNCTION,N/A,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 01:13:23,,1324606311,7/17/2014 01:13:15,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assess,N/A,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 01:32:42,,1324625370,7/17/2014 01:32:23,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assess,N/A,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 01:46:29,,1324639058,7/17/2014 01:46:11,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],out patient procedure,n/a,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 02:04:15,,1324656780,7/17/2014 02:03:18,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRACORPOREAL PAPAVERINE ERECTILE DYSFUNCTION,n/a,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 02:19:17,,1324671335,7/17/2014 02:18:25,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRACORPOREAL PAPAVERINE ERECTILE DYSFUNCTION,n/a,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 02:19:44,,1324671847,7/17/2014 02:19:13,clixsense,1.0,17548588,CAN,ON,New Hamburg,99.241.226.64,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],procedure assess,n/a,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 04:18:34,,1324786643,7/17/2014 04:17:56,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],procedure to assess,N/a,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 04:20:48,,1324788649,7/17/2014 04:20:36,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],used,N/A,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 05:05:01,,1324829328,7/17/2014 05:04:10,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRACORPOREAL PAPAVERINE ERECTILE DYSFUNCTION,N/A,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 05:20:56,,1324843993,7/17/2014 05:20:31,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],procedure to assess,N/A,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544846,7/17/2014 05:22:00,,1324844827,7/17/2014 05:21:38,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],procedure to assess,N/A,82,0,101,25,1,RO-may_diagnose,906591-FS1,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE
503544847,7/16/2014 20:24:47,,1324459756,7/16/2014 20:24:16,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],major complications,N/A,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/16/2014 20:26:58,,1324460772,7/16/2014 20:26:44,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],complications,Na,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/16/2014 20:29:42,,1324462077,7/16/2014 20:29:21,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],treatment of,N/A,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/16/2014 20:43:09,,1324467478,7/16/2014 20:42:40,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[SYMPTOM],[SYMPTOM],complications,Na,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/16/2014 20:56:37,,1324472947,7/16/2014 20:55:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM] [SIDE_EFFECT],"[SYMPTOM]
[SIDE_EFFECT]",The occurrence is,N/A,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/16/2014 21:37:02,,1324492887,7/16/2014 21:36:10,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[SIDE_EFFECT],[SIDE_EFFECT],VIII (FVIII) INHIBITORS is complications of the treatment of HAEMOPHILIA A,N/A,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/16/2014 21:40:20,,1324494154,7/16/2014 21:39:12,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[SIDE_EFFECT],[SIDE_EFFECT],major complications,n/a,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/16/2014 21:48:28,,1324497346,7/16/2014 21:48:15,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[NONE],[NONE],N/A,Differences,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/16/2014 22:36:54,,1324516275,7/16/2014 22:36:07,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES] [SYMPTOM] [MANIFESTATION] [SIDE_EFFECT],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[SIDE_EFFECT]",is one of the major complications of the treatment of,N/A,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/16/2014 23:56:52,,1324548403,7/16/2014 23:56:22,gifthulk,1,21916793,GBR,"","",87.115.178.12,[CAUSES],[CAUSES],occurrence of factor VIII INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A,N/A,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/17/2014 01:41:39,,1324634324,7/17/2014 01:40:53,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",occurrence factor VIII (FVIII) INHIBITORS major complications treatment of HAEMOPHILIA,N/A,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/17/2014 02:33:24,,1324685584,7/17/2014 02:33:07,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treatment,none,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/17/2014 04:10:57,,1324780219,7/17/2014 04:10:16,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[SIDE_EFFECT],[SIDE_EFFECT],is one of the major complications,"because of this sentence:

The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A",103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/17/2014 04:22:38,,1324790413,7/17/2014 04:22:01,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[SIDE_EFFECT],[SIDE_EFFECT],one of the major complications,N/a,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544847,7/17/2014 04:35:20,,1324802051,7/17/2014 04:34:27,elite,1.0,27788262,USA,"","",172.129.33.133,[SYMPTOM],[SYMPTOM],is one of the major complications of the treatment of,N/A,103,25,115,48,-1,RO-has_manifestation,906352-FS1,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS
503544848,7/16/2014 20:25:27,,1324460079,7/16/2014 20:24:34,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[SYMPTOM],[SYMPTOM],characterized by,n/a,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 20:25:49,,1324460209,7/16/2014 20:25:32,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],characterized by,N/A,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 20:46:49,,1324468959,7/16/2014 20:46:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],characterized by,N/A,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 21:00:44,,1324474996,7/16/2014 21:00:08,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[SYMPTOM],[SYMPTOM],characterized,Na,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 21:01:58,,1324475729,7/16/2014 21:01:49,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[MANIFESTATION],[MANIFESTATION],ABNORMALITIES,NONE,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 21:06:03,,1324477965,7/16/2014 21:04:45,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",characterized,n/a,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 21:27:15,,1324489052,7/16/2014 21:26:11,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],PAGET'S DISEASE characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND,n/a,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 21:33:42,,1324491558,7/16/2014 21:32:51,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",PAGET'S DISEASE characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE,N/A,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 21:48:42,,1324497485,7/16/2014 21:48:29,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],characterized,N/A,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 22:33:40,,1324514703,7/16/2014 22:33:27,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[SYMPTOM],[SYMPTOM],characterized,N/A,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 22:58:46,,1324524828,7/16/2014 22:57:46,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],PAGET'S DISEASE is disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE,N/A,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/16/2014 23:26:21,,1324536079,7/16/2014 23:26:03,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],characterized,N/A,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/17/2014 00:53:29,,1324587356,7/17/2014 00:52:24,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[MANIFESTATION],[MANIFESTATION],characterized,N/A,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/17/2014 01:12:47,,1324605830,7/17/2014 01:12:37,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],characterized,N/A,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544848,7/17/2014 02:17:24,,1324669442,7/17/2014 02:15:35,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[SYMPTOM],[SYMPTOM],PAGET'S DISEASE ABNORMALITIES OF BONE TURNOVER STRUCTURE,n/a,61,0,100,15,1,RO-has_finding_site,905143-FS1,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
503544849,7/16/2014 20:24:03,,1324459430,7/16/2014 20:23:47,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],presenting,Na,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/16/2014 21:02:19,,1324475903,7/16/2014 21:02:11,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[PREVENTS],[PREVENTS],PERIADENITIS.,NONE,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/16/2014 21:15:47,,1324483899,7/16/2014 21:15:22,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[SYMPTOM],[SYMPTOM],presenting,N/A,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/16/2014 21:37:56,,1324493163,7/16/2014 21:37:04,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[SIDE_EFFECT],[SIDE_EFFECT],treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,N/A,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/16/2014 21:38:37,,1324493407,7/16/2014 21:37:55,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SYMPTOM],[SYMPTOM],presenting a,N/A,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/16/2014 22:30:41,,1324513601,7/16/2014 22:30:07,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[MANIFESTATION],[MANIFESTATION],presenting a,na,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/16/2014 22:55:37,,1324523658,7/16/2014 22:55:02,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated items,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/16/2014 23:03:39,,1324526512,7/16/2014 23:03:02,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[SYMPTOM],[SYMPTOM],presenting,n/a,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/16/2014 23:56:21,,1324548228,7/16/2014 23:55:51,gifthulk,1.0,21916793,GBR,"","",87.115.178.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,N/A,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/17/2014 02:11:44,,1324664136,7/17/2014 02:11:07,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[SYMPTOM],[SYMPTOM],presenting,n/a,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/17/2014 03:52:49,,1324763339,7/17/2014 03:50:56,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",treated CHRONIC LYMPHOCYTIC LEUKAEMIA presenting right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,N/A,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/17/2014 05:19:31,,1324842591,7/17/2014 05:18:56,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],presenting,N/A,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/17/2014 05:20:45,,1324843771,7/17/2014 05:20:27,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],presenting a,n/a,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/17/2014 05:28:09,,1324849501,7/17/2014 05:27:21,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[SYMPTOM],[SYMPTOM],presenting a right,"because of this:

atient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.",109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544849,7/17/2014 05:31:38,,1324852036,7/17/2014 05:30:26,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[ASSOCIATED_WITH] [SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]",presenting,N/A,109,60,163,89,1,RO-disease_may_have_finding,902791-FS1,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
503544850,7/16/2014 20:20:50,,1324458024,7/16/2014 20:20:33,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],identified.,Na,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/16/2014 20:28:15,,1324461428,7/16/2014 20:27:45,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with SPORADIC OPCA and patients with SCA1,N/A,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/16/2014 20:32:05,,1324463068,7/16/2014 20:31:46,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,Different medical conditions,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/16/2014 20:33:47,,1324463736,7/16/2014 20:33:31,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],with,N/A,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/16/2014 20:52:07,,1324471220,7/16/2014 20:51:42,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the fibres were not identified.,n/a,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/16/2014 21:13:14,,1324482665,7/16/2014 21:12:56,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/16/2014 22:36:39,,1324516154,7/16/2014 22:36:24,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/16/2014 22:38:41,,1324517092,7/16/2014 22:37:57,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION] [ASSOCIATED_WITH],"[LOCATION]
[ASSOCIATED_WITH]",and in four five patients with,N/A,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/16/2014 23:25:22,,1324535674,7/16/2014 23:25:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/17/2014 04:10:16,,1324779571,7/17/2014 04:09:33,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[NONE],[NONE],N/A,N/A,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/17/2014 04:23:32,,1324791357,7/17/2014 04:23:04,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/a,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/17/2014 04:42:03,,1324807889,7/17/2014 04:41:40,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/17/2014 05:30:18,,1324851160,7/17/2014 05:29:14,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],in two patients with and in four of five patients with,N/A,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/17/2014 05:36:11,,1324855521,7/17/2014 05:35:41,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different conditions,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544850,7/17/2014 06:44:16,,1324913640,7/17/2014 06:41:53,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were not identified.,na,34,82,46,86,-1,RO-has_manifestation,906113-FS1,"In contrast, in two patients with SPORADIC OPCA and in four of five patients with SCA1 the fibres were not identified.",SPORADIC OPCA,SCA1
503544851,7/16/2014 20:28:14,,1324461418,7/16/2014 20:27:44,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],children,asd,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/16/2014 20:31:05,,1324462683,7/16/2014 20:30:45,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC DERMATITIS and ATOPIC FAMILIES WITHOUT CONCOMITANT,N/A,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/16/2014 20:32:19,,1324463171,7/16/2014 20:31:33,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[PART_OF],[PART_OF],and in members of,N/A,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/16/2014 20:34:56,,1324464174,7/16/2014 20:34:28,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are part of two separate groups.,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/16/2014 21:11:39,,1324481467,7/16/2014 21:11:11,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in,N/A,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/16/2014 22:19:23,,1324508782,7/16/2014 22:18:20,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC DERMATITIS members of ATOPIC FAMILIES WITHOUT CONCOMITANT,n/a,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/16/2014 23:05:36,,1324527164,7/16/2014 23:04:13,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[NONE],[NONE],n.A,nothing states linkage other than related to another problem,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/16/2014 23:10:53,,1324529002,7/16/2014 23:10:28,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],and,n/a,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/17/2014 00:28:54,,1324565100,7/17/2014 00:28:11,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in members of,N/A,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/17/2014 01:33:36,,1324626315,7/17/2014 01:33:10,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in,N/A,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/17/2014 01:41:02,,1324633814,7/17/2014 01:39:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/17/2014 05:26:43,,1324848326,7/17/2014 05:26:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],ATOPIC ATOPIC,N/A,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/17/2014 05:29:14,,1324850295,7/17/2014 05:28:11,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[PART_OF],[PART_OF],and in members of,"because it is a part of that illness:

 ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT",32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/17/2014 05:41:57,,1324860201,7/17/2014 05:41:26,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[NONE],[NONE],N/A,different conditions,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544851,7/17/2014 06:46:41,,1324916066,7/17/2014 06:46:11,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],in members,na,32,68,48,103,-1,RO-cause_of,900373-FS1,It also occurs in children with ATOPIC DERMATITIS and in members of ATOPIC FAMILIES WITHOUT CONCOMITANT bronchial asthma.,ATOPIC DERMATITIS,ATOPIC FAMILIES WITHOUT CONCOMITANT
503544852,7/16/2014 20:36:12,,1324464681,7/16/2014 20:35:47,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],normal with,n/a,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/16/2014 20:50:07,,1324470461,7/16/2014 20:49:40,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studied:,Na,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/16/2014 20:50:50,,1324470716,7/16/2014 20:50:26,clixsense,1.0,6500439,AUS,07,Wattle Grove,101.116.43.71,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were studied:,n/a,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/16/2014 21:02:09,,1324475825,7/16/2014 21:02:00,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRAEPITHELIAL NEOPLASIA,NONE,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/16/2014 21:31:22,,1324490636,7/16/2014 21:30:28,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CERVIX CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN,n/a,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/16/2014 21:46:58,,1324496849,7/16/2014 21:46:43,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],with,N/A,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/16/2014 23:03:53,,1324526594,7/16/2014 23:03:22,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],1924 women were studied:,n/a,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/16/2014 23:25:51,,1324535878,7/16/2014 23:25:39,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/17/2014 01:22:02,,1324614084,7/17/2014 01:21:40,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],normal CERVIX with CERVICAL INTRAEPITHELIAL NEOPLASIA,n/a,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/17/2014 01:28:42,,1324621266,7/17/2014 01:27:30,prodege,1.0,15532678,USA,NV,Las Vegas,72.193.104.50,[LOCATION],[LOCATION],CERVIX with CERVICAL INTRAEPITHELIAL NEOPLASIA,N/A,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/17/2014 01:36:22,,1324629055,7/17/2014 01:36:01,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[LOCATION],[LOCATION],normal CERVIX with,N/A,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/17/2014 02:26:16,,1324678136,7/17/2014 02:25:51,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,none,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/17/2014 04:09:32,,1324779041,7/17/2014 04:08:43,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[TREATS],[TREATS],with,"i think because of this.

with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),",57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/17/2014 04:34:25,,1324801408,7/17/2014 04:33:39,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544852,7/17/2014 05:17:22,,1324840522,7/17/2014 05:16:42,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],CERVIX CERVICAL,N/A,57,75,62,117,1,RO-disease_has_primary_anatomic_site,902157-FS1,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I)
503544853,7/16/2014 20:30:03,,1324462230,7/16/2014 20:29:43,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,Eight is just a number. It is not linked with the other term.,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/16/2014 20:31:01,,1324462660,7/16/2014 20:30:29,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,Eight is quantitative.,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/16/2014 20:55:18,,1324472475,7/16/2014 20:54:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],analyzed by,N/A,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/16/2014 21:09:05,,1324479766,7/16/2014 21:08:45,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[OTHER],[OTHER],of these,N/A,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/16/2014 21:31:10,,1324490564,7/16/2014 21:30:00,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[OTHER],[OTHER],EIGHT of these MALIGNANT MELANOMAS,N/A,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/16/2014 21:32:31,,1324491083,7/16/2014 21:31:22,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of these,n/a,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/16/2014 21:42:34,,1324494937,7/16/2014 21:41:35,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,"just a number of melanomas, not really related in any sense",8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/16/2014 22:57:31,,1324524411,7/16/2014 22:56:56,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER] [PART_OF],"[PART_OF]
[OTHER]",of these small,n/a,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/17/2014 00:20:48,,1324559549,7/17/2014 00:19:51,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[OTHER],[OTHER],of these,N/A,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/17/2014 01:12:59,,1324606004,7/17/2014 01:12:48,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[NONE],[NONE],N/A,No relation,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/17/2014 01:17:33,,1324610088,7/17/2014 01:17:05,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,"just a statistic, no relationship defined above",8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/17/2014 02:04:17,,1324656796,7/17/2014 02:03:17,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EIGHT MALIGNANT MELANOMAS,n/a,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/17/2014 02:09:07,,1324661734,7/17/2014 02:06:42,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],Four of EIGHT,n/a,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/17/2014 02:26:46,,1324678737,7/17/2014 02:26:17,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],these,none,8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544853,7/17/2014 04:11:46,,1324780944,7/17/2014 04:10:31,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[NONE],[NONE],n/a,"It's just a number, not a medical term",8,29,12,48,-1,RO-has_manifestation,906238-FS1,Four of EIGHT of these small MALIGNANT MELANOMAS analyzed by multiparameter flow cytometry were aneuploid (DNA ploidy index less than or equal to 0.9 or greater than or equal to 1.1.,EIGHT,MALIGNANT MELANOMAS
503544854,7/16/2014 20:25:54,,1324460261,7/16/2014 20:25:32,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recorded,N/A,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 20:27:13,,1324460928,7/16/2014 20:27:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],incidence,Na,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 20:37:15,,1324465157,7/16/2014 20:36:49,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PART_OF],[PART_OF],groups,asd,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 20:45:30,,1324468344,7/16/2014 20:44:23,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],recorded by,N/A,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 20:57:21,,1324473166,7/16/2014 20:56:35,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ONDANSETRON,NONE,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 21:06:12,,1324478023,7/16/2014 21:05:46,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recorded by,N/A,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 21:34:33,,1324491898,7/16/2014 21:33:46,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",recorded by the,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 21:38:07,,1324493215,7/16/2014 21:37:16,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recorded by,n/a,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 21:42:14,,1324494834,7/16/2014 21:42:03,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recorded,N/A,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 22:25:57,,1324511468,7/16/2014 22:25:42,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,unclear,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 22:41:56,,1324518301,7/16/2014 22:41:31,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],recorded by,N/A,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 22:45:38,,1324519571,7/16/2014 22:44:33,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recorded by,na,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 22:52:21,,1324522222,7/16/2014 22:51:18,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],recorded by,n/a,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 23:09:28,,1324528476,7/16/2014 23:09:01,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recorded by the,na,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544854,7/16/2014 23:25:54,,1324535907,7/16/2014 23:25:27,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[SYMPTOM],[SYMPTOM],lower incidence recorded by,N/A,23,46,28,57,1,RO-may_prevent,907449-FS1,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
503544855,7/16/2014 20:28:21,,1324461491,7/16/2014 20:27:44,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to detect the,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/16/2014 20:41:14,,1324466766,7/16/2014 20:40:56,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to detect,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/16/2014 21:27:46,,1324489222,7/16/2014 21:27:22,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to detect the,[DIAGNOSE_BY_TEST_OR_DRUG],92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/16/2014 22:32:23,,1324514206,7/16/2014 22:31:40,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to detect,na,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/16/2014 22:33:26,,1324514592,7/16/2014 22:33:12,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detect,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/16/2014 22:39:42,,1324517477,7/16/2014 22:39:21,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to detect the,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/16/2014 23:09:07,,1324528351,7/16/2014 23:08:25,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/16/2014 23:25:26,,1324535697,7/16/2014 23:25:10,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to detect,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/17/2014 01:12:23,,1324605380,7/17/2014 01:12:08,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to detect the,n/a,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/17/2014 01:27:17,,1324619630,7/17/2014 01:26:55,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detect,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/17/2014 02:20:01,,1324672122,7/17/2014 02:19:19,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[SYMPTOM],[SYMPTOM],HALOTHANE MALIGNANT HYPERTHERMIA SYNDROME,n/a,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/17/2014 04:21:57,,1324789857,7/17/2014 04:21:47,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detect,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/17/2014 04:22:26,,1324790225,7/17/2014 04:21:52,elite,1.0,27788262,USA,"","",172.129.33.133,[PREVENTS],[PREVENTS],to detect the,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/17/2014 04:38:58,,1324805185,7/17/2014 04:38:28,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were challenged with HALOTHANE detect MALIGNANT HYPERTHERMIA SYNDROME,N/A,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544855,7/17/2014 05:21:52,,1324844688,7/17/2014 05:21:34,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detect,n/a,92,68,122,77,1,RO-may_diagnose,906757-FS1,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE
503544856,7/16/2014 20:20:02,,1324457682,7/16/2014 20:19:22,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PREVENTS],[PREVENTS],immunisation,N/A,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/16/2014 20:24:31,,1324459665,7/16/2014 20:24:17,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",immunisation,Na,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/16/2014 20:26:02,,1324460323,7/16/2014 20:25:43,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],recombinant HEPATITIS B VACCINE HEPATITIS B INFECTION,N/A,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/16/2014 20:29:10,,1324461839,7/16/2014 20:28:46,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[PREVENTS],[PREVENTS],recombinant,N/A,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/16/2014 20:38:41,,1324465679,7/16/2014 20:38:16,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and the origin and evolution of,n/a,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/16/2014 21:37:54,,1324493144,7/16/2014 21:36:37,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[PREVENTS],[PREVENTS],the immunisation of,N/A,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/16/2014 22:38:39,,1324517082,7/16/2014 22:37:40,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],immunisation,N/A,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/16/2014 23:00:34,,1324525369,7/16/2014 22:59:15,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/16/2014 23:06:58,,1324527653,7/16/2014 23:06:16,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[TREATS],[TREATS],immunisation,n/a,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/16/2014 23:18:03,,1324531929,7/16/2014 23:17:18,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PREVENTS],[PREVENTS],"HEPATITIS B VACCINE are described, evolution of HEPATITIS B INFECTION",N/A,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/17/2014 00:25:31,,1324562159,7/17/2014 00:22:42,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"described, origin evolution",N/A,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/17/2014 01:39:37,,1324632526,7/17/2014 01:38:25,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PREVENTS],[PREVENTS],VACCINE,n/a,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/17/2014 02:09:44,,1324662243,7/17/2014 02:07:26,clixsense,1.0,17548588,CAN,ON,New Hamburg,99.241.226.64,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",recombinant HEPATITIS B VACCINE,n/a,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/17/2014 04:08:42,,1324778374,7/17/2014 04:07:55,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[OTHER],[OTHER],and the origin,"because of

 recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544856,7/17/2014 05:22:56,,1324845600,7/17/2014 05:21:53,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PREVENTS],[PREVENTS],immunisation,n/a,218,151,238,170,1,RO-may_prevent,907208-FS1,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
503544857,7/16/2014 20:26:50,,1324460684,7/16/2014 20:26:38,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has been implicated,N/A,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/16/2014 20:27:33,,1324461080,7/16/2014 20:27:14,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],neurocognitive,Na,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/16/2014 20:30:24,,1324462411,7/16/2014 20:30:06,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],IMMUNODEFICIENCY,asd,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/16/2014 20:31:37,,1324462898,7/16/2014 20:31:19,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/16/2014 20:47:50,,1324469432,7/16/2014 20:47:21,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],(HIV),N/A,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/16/2014 20:49:02,,1324470009,7/16/2014 20:48:38,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/16/2014 21:25:32,,1324488257,7/16/2014 21:24:14,clixsense,1.0,15189335,GBR,H9,London,188.29.165.176,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,Na,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/16/2014 21:40:29,,1324494210,7/16/2014 21:37:56,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[MANIFESTATION],[MANIFESTATION],HUMAN IMMUNODEFICIENCY VIRUS (HIV) HIV INFECTION,N/A,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/16/2014 22:32:07,,1324514129,7/16/2014 22:31:37,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],implicated in pathophysiology the neurocognitive deficits associated with,N/A,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/16/2014 22:40:26,,1324517789,7/16/2014 22:39:59,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has been implicated,N/A,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/17/2014 01:07:09,,1324600539,7/17/2014 01:06:39,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],implicated in the pathophysiology of the neurocognitive deficits associated,N/A,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/17/2014 01:46:10,,1324638732,7/17/2014 01:45:02,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/17/2014 02:11:12,,1324663627,7/17/2014 02:10:17,clixsense,1.0,17548588,CAN,ON,New Hamburg,99.241.226.64,[MANIFESTATION],[MANIFESTATION],HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated the pathophysiology of neurocognitive deficits HIV,n/a,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/17/2014 02:21:08,,1324673155,7/17/2014 02:20:47,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,none,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544857,7/17/2014 02:28:40,,1324680807,7/17/2014 02:27:26,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION,n/a,23,148,56,161,1,RO-has_causative_agent,903769-FS1,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION
503544858,7/16/2014 20:20:35,,1324457928,7/16/2014 20:20:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],in the pathogenesis of,N/A,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/16/2014 20:25:11,,1324459960,7/16/2014 20:24:24,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],PRION PROTEIN pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,N/A,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/16/2014 20:28:51,,1324461692,7/16/2014 20:28:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is another,N/A,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/16/2014 20:35:35,,1324464441,7/16/2014 20:35:16,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],involvement,N/A,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/16/2014 20:35:37,,1324464454,7/16/2014 20:35:06,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],PRION PROTEIN,asd,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/16/2014 21:32:09,,1324490916,7/16/2014 21:31:12,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[CAUSES],[CAUSES],PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,N/A,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/16/2014 22:25:40,,1324511340,7/16/2014 22:25:26,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[CAUSES],[CAUSES],pathogenesis,N/A,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/16/2014 22:58:38,,1324524803,7/16/2014 22:56:57,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],in the pathogenesis of,na,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/16/2014 23:13:20,,1324529952,7/16/2014 23:12:43,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,N/A,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/16/2014 23:13:33,,1324530103,7/16/2014 23:12:22,clixsense,1.0,11338264,CAN,ON,Aurora,184.148.114.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],involvement PRION PROTEIN pathogenesis of TRANSMISSIBLE,N/a,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/17/2014 00:32:01,,1324567556,7/17/2014 00:31:36,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the pathogenesis of,N/A,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/17/2014 01:42:19,,1324635025,7/17/2014 01:41:41,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[PART_OF] [MANIFESTATION],"[MANIFESTATION]
[PART_OF]",involvement PRION PROTEIN pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,N/A,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/17/2014 02:06:14,,1324658766,7/17/2014 02:05:22,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PRION PROTEIN TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,n/a,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/17/2014 02:06:41,,1324659270,7/17/2014 02:05:39,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],pathogenesis,n/a,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544858,7/17/2014 02:33:48,,1324686014,7/17/2014 02:33:24,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[CAUSES],[CAUSES],involvement,none,196,233,208,272,1,RO-has_causative_agent,903808-FS1,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
503544859,7/16/2014 20:20:30,,1324457868,7/16/2014 20:20:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],mutations,Na,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/16/2014 20:23:13,,1324459151,7/16/2014 20:22:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],the role of,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/16/2014 20:34:06,,1324463875,7/16/2014 20:33:48,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],gene,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/16/2014 21:10:14,,1324480552,7/16/2014 21:09:58,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[PART_OF],[PART_OF],in,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/16/2014 21:34:12,,1324491774,7/16/2014 21:31:46,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],gene in,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/16/2014 23:19:34,,1324532661,7/16/2014 23:17:22,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[SYMPTOM],[SYMPTOM],mutations,n/a,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/16/2014 23:19:48,,1324532824,7/16/2014 23:19:23,superrewards,1,26561650,NLD,06,Tilburg,84.87.179.65,[LOCATION],[LOCATION],in,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/17/2014 00:18:04,,1324557999,7/17/2014 00:16:17,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],investigated the role of,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/17/2014 01:13:49,,1324606716,7/17/2014 01:13:33,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],investigated the role of somatic mutations,n/a,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/17/2014 01:28:17,,1324620748,7/17/2014 01:27:57,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[LOCATION],[LOCATION],in,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/17/2014 01:59:22,,1324651931,7/17/2014 01:58:49,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],in,n/a,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/17/2014 04:40:22,,1324806214,7/17/2014 04:39:15,elite,1.0,27788262,USA,"","",172.129.33.133,[LOCATION],[LOCATION],in,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/17/2014 05:11:07,,1324834872,7/17/2014 05:10:22,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],mutations of in,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/17/2014 05:34:55,,1324854494,7/17/2014 05:33:50,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",role of,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544859,7/17/2014 05:39:03,,1324857888,7/17/2014 05:38:38,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[ASSOCIATED_WITH],[ASSOCIATED_WITH],gene in,N/A,101,62,119,86,-1,RO-has_manifestation,906483-FS1,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2
503544860,7/16/2014 20:31:22,,1324462804,7/16/2014 20:31:07,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],SKIN TUMORS including NEVUS CELL NEVUS,N/A,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 20:33:13,,1324463504,7/16/2014 20:32:48,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[LOCATION],[LOCATION],other,N/A,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 20:44:21,,1324467907,7/16/2014 20:43:24,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],was including,N/A,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 20:48:23,,1324469698,7/16/2014 20:47:45,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,Na,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 21:43:39,,1324495465,7/16/2014 21:43:26,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 21:46:45,,1324496781,7/16/2014 21:45:31,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",SKIN TUMORS including NEVUS CELL NEVUS,N/A,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 22:17:33,,1324508020,7/16/2014 22:16:23,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],other SKIN TUMORS NEVUS CELL NEVUS,n/a,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 22:28:41,,1324512794,7/16/2014 22:27:36,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[IS_A],[IS_A],other including,na,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 22:33:54,,1324514790,7/16/2014 22:33:42,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],CELL,N/A,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 22:47:29,,1324520426,7/16/2014 22:46:32,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],no positive reactivity,N/A,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/16/2014 23:15:30,,1324530785,7/16/2014 23:13:34,clixsense,1.0,11338264,CAN,ON,Aurora,184.148.114.225,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",other SKIN TUMORS including CELL,N/a,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/17/2014 01:16:50,,1324609381,7/17/2014 01:16:40,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SKIN CELL,N/A,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/17/2014 01:33:08,,1324625892,7/17/2014 01:32:42,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[PART_OF],[PART_OF],including,N/A,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/17/2014 02:15:32,,1324667664,7/17/2014 02:15:04,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SKIN TUMORS NEVUS CELL NEVUS,n/a,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544860,7/17/2014 02:24:39,,1324676564,7/17/2014 02:24:17,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,67,164,77,180,1,RO-has_finding_site,905154-FS1,"There was no positive reactivity of anti D 1 antibodies with other SKIN TUMORS including squamous cell carcinoma, basal cell epithelioma, seborrheic keratosis, and NEVUS CELL NEVUS",SKIN TUMORS,NEVUS CELL NEVUS
503544861,7/16/2014 20:23:16,,1324459172,7/16/2014 20:23:01,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/16/2014 20:36:07,,1324464664,7/16/2014 20:34:57,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[MANIFESTATION],[MANIFESTATION],divided into,n/a,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/16/2014 20:45:37,,1324468394,7/16/2014 20:43:10,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[ASSOCIATED_WITH],[ASSOCIATED_WITH],following categories:,Na,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/16/2014 21:02:44,,1324476125,7/16/2014 20:59:55,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",includes,N/A,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/16/2014 21:08:44,,1324479560,7/16/2014 21:08:29,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/16/2014 21:24:22,,1324487732,7/16/2014 21:21:36,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],terminology squamous epithelial lesions includes MILD DYSPLASIA cervical INTRAEPITHELIAL NEOPLASIA [CIN],n/a,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/16/2014 23:12:24,,1324529633,7/16/2014 23:11:43,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/17/2014 00:14:19,,1324556466,7/17/2014 00:13:22,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"associated cellular changes,",N/A,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/17/2014 00:27:05,,1324563389,7/17/2014 00:25:32,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/17/2014 01:46:37,,1324639184,7/17/2014 01:45:49,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"squamous cell carcinoma precursors, MILD DYSPLASIA and INTRAEPITHELIAL NEOPLASIA",N/A,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/17/2014 01:52:17,,1324644902,7/17/2014 01:51:10,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MILD DYSPLASIA INTRAEPITHELIAL NEOPLASIA [CIN],n/a,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/17/2014 02:30:23,,1324682387,7/17/2014 02:29:36,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MILD DYSPLASIA INTRAEPITHELIAL NEOPLASIA [CIN],n/a,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/17/2014 02:30:53,,1324682936,7/17/2014 02:30:32,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/17/2014 04:17:43,,1324785869,7/17/2014 04:17:30,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544861,7/17/2014 04:42:31,,1324808396,7/17/2014 04:42:05,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN],336,364,349,397,-1,RO-disease_has_finding,901595-FS1,"The terminology for squamous epithelial lesions includes the following categories: 1) atypical squamous cells of undetermined significance; 2) squamous intraepithelial lesion (SIL), which encompasses the spectrum of squamous cell carcinoma precursors, divided into low grade SIL (human papillomavirus [HPV] associated cellular changes, MILD DYSPLASIA and cervical INTRAEPITHELIAL NEOPLASIA [CIN] I and high grade SIL (moderate dysplasia, severe dysplasia, and carcinoma in situ and CIN II and III); and 3) squamous cell carcinoma.",MILD DYSPLASIA,INTRAEPITHELIAL NEOPLASIA [CIN] I
503544862,7/16/2014 20:34:27,,1324463989,7/16/2014 20:33:14,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],drug treatment,N/A,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/16/2014 20:36:53,,1324464994,7/16/2014 20:36:13,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],consider,N/A,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/16/2014 20:46:54,,1324468996,7/16/2014 20:45:47,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],consider transformation,n/a,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/16/2014 21:16:50,,1324484421,7/16/2014 21:16:09,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],LYMPHADENOPATHY consider CLL transformation,n/a,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/16/2014 21:35:09,,1324492129,7/16/2014 21:34:18,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[TREATS],[TREATS],consider drug treatment,n/a,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/16/2014 22:37:25,,1324516570,7/16/2014 22:36:28,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],consider CLL,na,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/16/2014 23:09:50,,1324528639,7/16/2014 23:09:06,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[TREATS],[TREATS],consider,n/a,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/16/2014 23:32:17,,1324538621,7/16/2014 23:31:35,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/17/2014 01:14:00,,1324606875,7/17/2014 01:13:52,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],treatment,N/A,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/17/2014 02:09:59,,1324662479,7/17/2014 02:09:02,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LYMPHADENOPATHY CLL,n/a,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/17/2014 04:00:47,,1324771672,7/17/2014 03:59:57,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[TREATS],[TREATS],rapidly advancing disease characterized massive LYMPHADENOPATHY CLL transformation,N/A,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/17/2014 04:08:59,,1324778621,7/17/2014 04:07:47,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[CAUSES],[CAUSES],consider CLL transformation,N/a,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/17/2014 04:15:43,,1324784120,7/17/2014 04:13:55,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,"LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation",82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/17/2014 04:17:29,,1324785689,7/17/2014 04:17:14,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],characterized,N/A,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544862,7/17/2014 05:24:45,,1324846864,7/17/2014 05:23:43,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],In patients with consider,N/A,82,131,96,134,1,RO-disease_may_have_finding,902686-FS1,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
503544863,7/16/2014 20:20:16,,1324457786,7/16/2014 20:20:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],found,Na,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 20:33:56,,1324463795,7/16/2014 20:33:18,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],is found in the with,N/A,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 20:45:02,,1324468160,7/16/2014 20:44:19,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is found in the,n/a,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 21:15:21,,1324483695,7/16/2014 21:14:37,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[LOCATION],[LOCATION],in the,N/A,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 21:25:26,,1324488215,7/16/2014 21:24:58,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in 5% of the patients,[DIAGNOSE_BY_TEST_OR_DRUG],20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 21:41:11,,1324494469,7/16/2014 21:40:24,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[LOCATION],[LOCATION],in the,n/a,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 21:46:18,,1324496605,7/16/2014 21:46:02,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],found,N/A,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 21:47:37,,1324497069,7/16/2014 21:47:09,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[LOCATION],[LOCATION],found in the,na,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 22:25:03,,1324511063,7/16/2014 22:24:46,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found in 5%,N/A,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 23:02:02,,1324525874,7/16/2014 23:01:07,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[LOCATION],[LOCATION],found in,n/a,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/16/2014 23:04:50,,1324526909,7/16/2014 23:03:27,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",CIS is found in the CONTRALATERAL TESTIS with TESTICULAR GERM CELL CANCER,N/A,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/17/2014 01:19:57,,1324612347,7/17/2014 01:19:37,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],found in the CONTRALATERAL TESTIS,n/a,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/17/2014 01:29:55,,1324622475,7/17/2014 01:27:00,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[MANIFESTATION],[MANIFESTATION],found in CONTRALATERAL TESTIS patients with TESTICULAR GERM CELL CANCER,N/A,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/17/2014 01:36:45,,1324629446,7/17/2014 01:36:23,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[LOCATION],[LOCATION],found in,N/A,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544863,7/17/2014 01:48:11,,1324640827,7/17/2014 01:46:30,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],found in the,n/a,20,68,39,95,1,RO-disease_has_primary_anatomic_site,902445-FS1,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER
503544864,7/16/2014 20:23:29,,1324459251,7/16/2014 20:23:14,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],found to be susceptible to,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/16/2014 20:36:38,,1324464902,7/16/2014 20:36:12,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",were found to be susceptible to,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/16/2014 20:38:06,,1324465424,7/16/2014 20:36:45,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[TREATS],[TREATS],susceptible to,Na,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/16/2014 20:40:55,,1324466655,7/16/2014 20:40:33,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],were found to be susceptible to,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/16/2014 20:45:26,,1324468316,7/16/2014 20:45:03,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were found to be susceptible to,n/a,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/16/2014 21:32:49,,1324491182,7/16/2014 21:32:10,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[TREATS],[TREATS],SALMONELLA ISOLATES susceptible to AMPICILLIN,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/16/2014 22:35:23,,1324515573,7/16/2014 22:35:08,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],susceptible to,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/16/2014 23:11:41,,1324529310,7/16/2014 23:11:15,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[TREATS],[TREATS],were found to be susceptible to,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/16/2014 23:19:21,,1324532559,7/16/2014 23:18:39,superrewards,1.0,26561650,NLD,06,Tilburg,84.87.179.65,[CONTRAINDICATES],[CONTRAINDICATES],susceptible to,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/16/2014 23:36:11,,1324540263,7/16/2014 23:35:55,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],susceptible,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/17/2014 00:29:53,,1324565859,7/17/2014 00:28:55,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[TREATS],[TREATS],found susceptible to,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/17/2014 01:18:08,,1324610604,7/17/2014 01:17:42,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[MANIFESTATION],[MANIFESTATION],were found to be,N/A,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/17/2014 01:57:04,,1324649584,7/17/2014 01:55:50,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SALMONELLA ISOLATES AMPICILLIN,n/a,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/17/2014 02:29:54,,1324681874,7/17/2014 02:29:29,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[SIDE_EFFECT],[SIDE_EFFECT],susceptible,none,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544864,7/17/2014 04:22:01,,1324789905,7/17/2014 04:21:16,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found to be susceptible,N/a,0,80,18,90,1,RO-may_treat,908309-FS1,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
503544865,7/16/2014 20:23:36,,1324459274,7/16/2014 20:22:22,zapbux,1,27754872,USA,SC,Graniteville,24.145.86.46,[MANIFESTATION],[MANIFESTATION],STRAINS,n/a,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/16/2014 20:29:21,,1324461937,7/16/2014 20:28:56,instagc,1.0,13763729,USA,"","",75.182.89.225,[PART_OF],[PART_OF],M TUBERCULOSIS STRAINS H37RV M TUBERCULOSIS,N/A,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/16/2014 20:50:24,,1324470559,7/16/2014 20:49:44,clixsense,1,6500439,AUS,07,Wattle Grove,101.116.43.71,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in the specimens,n/a,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/16/2014 21:23:33,,1324487325,7/16/2014 21:22:54,clixsense,1.0,15189335,GBR,H9,London,188.29.165.176,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 01:25:51,,1324618005,7/17/2014 01:25:29,neodev,1,21405167,USA,MD,Dundalk,66.87.82.199,[IS_A],[IS_A],TUBERCULOSIS TUBERCULOSIS,N/A,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 02:03:33,,1324656088,7/17/2014 02:01:37,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],STRAINS in the specimens,n/a,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 04:06:58,,1324776790,7/17/2014 04:06:10,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the specimens painted for microscopy.,N/a,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 04:22:26,,1324790229,7/17/2014 04:22:14,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 05:03:04,,1324827519,7/17/2014 05:02:03,prodege,1,27934334,GBR,"","",86.130.153.15,[OTHER],[OTHER],STRAINS,N/A,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 05:18:32,,1324841754,7/17/2014 05:17:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],M TUBERCULOSIS M TUBERCULOSIS,N/A,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 05:23:08,,1324845839,7/17/2014 05:21:26,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[IS_A],[IS_A],specimens,na,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 05:27:20,,1324848908,7/17/2014 05:26:26,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[PART_OF],[PART_OF],and and,"because of 

and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 05:38:36,,1324857514,7/17/2014 05:38:01,neodev,1,14861092,GBR,H9,London,90.194.156.173,[CAUSES],[CAUSES],M TUBERCULOSIS STRAINS M TUBERCULOSIS,N/A,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 06:46:08,,1324915622,7/17/2014 06:45:34,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],with,na,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544865,7/17/2014 07:18:05,,1324949458,7/17/2014 07:17:08,paiddailysurveys,1,11786001,USA,NC,Matthews,71.28.92.249,[PART_OF],[PART_OF],M TUBERCULOSIS STRAINS and M TUBERCULOSIS,N/A,220,220,247,234,-1,RO-has_causative_agent,903535-FS1,"Spoligotyping was used for genotyping of 238 M. tuberculosis cultures isolated from 302 patients with pulmonary tuberculosis living in the north west of Russia, including those in Saint Petersburg, in 1998 2001, and the M TUBERCULOSIS STRAINS H37RV M. bovis, and M. bovic BCG and M TUBERCULOSIS in the specimens painted for microscopy.",M TUBERCULOSIS STRAINS H37RV,M TUBERCULOSIS
503544866,7/16/2014 20:22:25,,1324458770,7/16/2014 20:22:08,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],characterized,Na,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 20:25:02,,1324459890,7/16/2014 20:24:48,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],characterized by,N/A,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 20:31:18,,1324462762,7/16/2014 20:30:51,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CONTRAINDICATES],[CONTRAINDICATES],WITH DYSPROTEINEMIA (AILD),asd,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 20:33:53,,1324463769,7/16/2014 20:31:31,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[SYMPTOM],[SYMPTOM],characterized by,n/a,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 20:46:20,,1324468737,7/16/2014 20:45:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],characterized by,N/A,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 21:02:15,,1324475883,7/16/2014 21:01:38,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DYSPROTEINEMIA (AILD) LYMPHADENOPATHY,N/A,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 21:15:01,,1324483581,7/16/2014 21:14:13,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",WITH DYSPROTEINEMIA (AILD) characterized by LYMPHADENOPATHY,n/a,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 21:17:32,,1324484798,7/16/2014 21:15:25,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],characterized by diffuse,[DIAGNOSE_BY_TEST_OR_DRUG],126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 21:49:21,,1324497700,7/16/2014 21:49:11,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],characterized,N/A,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 22:24:20,,1324510813,7/16/2014 22:24:07,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[SYMPTOM],[SYMPTOM],characterized by,N/A,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 22:25:29,,1324511226,7/16/2014 22:25:03,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],characterized by diffuse,N/A,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/16/2014 22:30:07,,1324513349,7/16/2014 22:29:13,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[SYMPTOM],[SYMPTOM],characterized by,na,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/17/2014 01:05:35,,1324599081,7/17/2014 01:05:16,bitcoinget,1,27806000,USA,TX,San Antonio,67.11.143.200,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],characterized,N/A,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/17/2014 01:14:10,,1324607003,7/17/2014 01:13:50,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],characterized by,n/a,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544866,7/17/2014 01:34:41,,1324627250,7/17/2014 01:31:55,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[SYMPTOM],[SYMPTOM],lymphadenopathy WITH DYSPROTEINEMIA (AILD) rare lymphoproliferative disorder characterized by LYMPHADENOPATHY,N/A,126,35,140,61,1,RO-disease_may_have_finding,902569-FS1,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD)
503544867,7/16/2014 20:24:18,,1324459562,7/16/2014 20:23:58,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are separate items in a list.,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/16/2014 20:27:44,,1324461133,7/16/2014 20:27:25,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],numerous side effects,N/A,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/16/2014 20:30:27,,1324462446,7/16/2014 20:30:14,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],JAUNDICE HEPATIC CARCINOMA,All one term,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/16/2014 20:36:46,,1324464933,7/16/2014 20:36:17,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[TREATS],[TREATS],JAUNDICE HEPATIC CARCINOMA,asd,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/16/2014 21:08:52,,1324479627,7/16/2014 21:08:16,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],including,N/A,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/16/2014 21:16:10,,1324484074,7/16/2014 21:15:48,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/16/2014 21:41:08,,1324494452,7/16/2014 21:40:19,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",numerous side effects,N/A,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/16/2014 22:36:07,,1324515943,7/16/2014 22:35:34,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],including,N/A,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/16/2014 22:39:31,,1324517408,7/16/2014 22:37:26,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[NONE],[NONE],na,the two terms are actually part of the same term.,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/16/2014 22:48:17,,1324520668,7/16/2014 22:47:50,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SIDE_EFFECT],[SIDE_EFFECT],numerous side effects,N/A,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/17/2014 01:14:11,,1324607008,7/17/2014 01:14:01,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],JAUNDICE HEPATIC CARCINOMA,N/A,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/17/2014 01:46:28,,1324639067,7/17/2014 01:45:18,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],JAUNDICE HEPATIC CARCINOMA,n/a,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/17/2014 03:53:42,,1324764161,7/17/2014 03:51:22,clixsense,1,6416927,USA,CA,San Francisco,107.130.18.82,[LOCATION],[LOCATION],HEPATIC,N/A,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/17/2014 04:11:34,,1324780791,7/17/2014 04:09:57,elite,1.0,27788262,USA,"","",172.129.33.133,[OTHER],[OTHER],JAUNDICE HEPATIC CARCINOMA,N/A,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544867,7/17/2014 04:15:26,,1324783885,7/17/2014 04:14:34,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[PART_OF],[PART_OF],JAUNDICE HEPATIC CARCINOMA,because this JAUNDICE HEPATIC CARCINOMA is one medical word!,114,123,121,140,-1,RO-disease_may_have_finding,902602-FS1,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA
503544868,7/16/2014 20:32:02,,1324463040,7/16/2014 20:31:38,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatments,N/A,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/16/2014 20:36:11,,1324464672,7/16/2014 20:35:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PLASMODIUM FALCIPARUM INFECTION disease MALARIA,N/A,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/16/2014 20:42:07,,1324467116,7/16/2014 20:41:16,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],uncomplicated falciparum,N/A,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/16/2014 20:43:33,,1324467605,7/16/2014 20:42:41,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combinations for treatment of malaria:,n/a,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/16/2014 21:18:56,,1324485385,7/16/2014 21:16:52,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[CAUSES],[CAUSES],disease,n/a,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/16/2014 21:49:43,,1324497827,7/16/2014 21:48:24,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[IS_A],[IS_A],Plasmodium falciparum malaria,na,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/16/2014 22:36:50,,1324516246,7/16/2014 22:36:40,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/17/2014 00:29:07,,1324565257,7/17/2014 00:27:51,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[CAUSES],[CAUSES],vaccine against for uncomplicated,N/A,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/17/2014 01:17:41,,1324610191,7/17/2014 01:16:01,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[NONE],[NONE],N/A,Listing different diseases,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/17/2014 01:35:03,,1324627634,7/17/2014 01:34:33,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[OTHER],[OTHER],Plasmodium falciparum malaria,N/A,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/17/2014 01:49:26,,1324641905,7/17/2014 01:48:12,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],Plasmodium falciparum malaria,n/a,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/17/2014 02:20:47,,1324672813,7/17/2014 02:20:21,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treatments,none,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/17/2014 04:15:44,,1324784118,7/17/2014 04:15:13,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/17/2014 04:16:53,,1324785115,7/17/2014 04:15:45,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial Combination treatments for uncomplicated falciparum MALARIA,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544868,7/17/2014 04:20:07,,1324788062,7/17/2014 04:19:20,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],vaccine against,N/a,246,398,276,405,-1,RO-has_causative_agent,903659-FS1,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA
503544869,7/16/2014 20:26:42,,1324460610,7/16/2014 20:26:20,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],HYPERTENSION ELEVATED BP,N/A,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/16/2014 20:28:47,,1324461659,7/16/2014 20:28:17,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[PREVENTS],[PREVENTS],HYPERTENSION,asd,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/16/2014 21:17:27,,1324484773,7/16/2014 21:17:09,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[SYMPTOM],[SYMPTOM],common among,N/A,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/16/2014 21:33:36,,1324491508,7/16/2014 21:32:33,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",associated with,n/a,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/16/2014 22:53:45,,1324522826,7/16/2014 22:53:02,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],common among ED patients with,n/a,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/16/2014 23:39:56,,1324541906,7/16/2014 23:39:34,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/17/2014 01:17:18,,1324609808,7/17/2014 01:17:07,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/17/2014 02:28:27,,1324680618,7/17/2014 02:28:01,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[CAUSES],[CAUSES],with,none,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/17/2014 04:18:39,,1324786751,7/17/2014 04:18:24,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/17/2014 04:55:39,,1324820110,7/17/2014 04:54:29,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],are common,n/a,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/17/2014 05:15:48,,1324839101,7/17/2014 05:15:12,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],common among patients with,N/A,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/17/2014 05:32:21,,1324852549,7/17/2014 05:31:27,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[SYMPTOM],[SYMPTOM],associated with,"because this part of the sentence:

We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP",100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/17/2014 05:35:13,,1324854812,7/17/2014 05:34:46,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[SYMPTOM],[SYMPTOM],are common among,N/A,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/17/2014 06:44:58,,1324914407,7/17/2014 06:44:18,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",symptoms associated with,na,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544869,7/17/2014 06:48:28,,1324917900,7/17/2014 06:47:41,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/a,100,53,110,65,-1,RO-has_definitional_manifestation,904506-FS1,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION
503544870,7/16/2014 20:22:56,,1324459012,7/16/2014 20:22:42,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],and other equivalents of,N/A,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/16/2014 20:23:58,,1324459397,7/16/2014 20:23:40,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],HEADACHE and other equivalents of CHILDHOOD MIGRAINE,N/A,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/16/2014 20:29:13,,1324461847,7/16/2014 20:28:59,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],HEADACHE other equivalents of CHILDHOOD MIGRAINE,N/A,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/16/2014 20:34:37,,1324464073,7/16/2014 20:34:14,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[LOCATION],[LOCATION],HEADACHE,asd,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/16/2014 20:36:32,,1324464836,7/16/2014 20:36:08,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[IS_A],[IS_A],and other equivalents,n/a,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/16/2014 20:42:29,,1324467250,7/16/2014 20:41:41,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is related,N/A,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/16/2014 21:24:23,,1324487743,7/16/2014 21:23:36,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",equivalents,n/a,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/16/2014 21:26:11,,1324488554,7/16/2014 21:24:13,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",HEADACHE equivalents of CHILDHOOD MIGRAINE,N/A,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/16/2014 21:48:02,,1324497212,7/16/2014 21:47:52,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],equivalents,N/A,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/16/2014 22:32:58,,1324514404,7/16/2014 22:32:24,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[IS_A],[IS_A],equivalents of,na,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/17/2014 01:28:40,,1324621215,7/17/2014 01:28:18,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[IS_A],[IS_A],equivalents,N/A,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/17/2014 01:58:48,,1324651353,7/17/2014 01:58:07,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],other equivalents of,n/a,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/17/2014 02:01:38,,1324654121,7/17/2014 02:00:53,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE CHILDHOOD MIGRAINE,n/a,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/17/2014 04:12:02,,1324781166,7/17/2014 04:11:35,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,HEADACHE and other equivalents of CHILDHOOD MIGRAINE,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544870,7/17/2014 05:01:12,,1324825604,7/17/2014 05:00:41,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[IS_A],[IS_A],HEADACHE other equivalents CHILDHOOD MIGRAINE is,N/A,82,116,89,134,-1,RO-has_definitional_manifestation,904903-FS1,"The pathogenesis of periodic syndrome (recurrent abdominal pain, cyclic vomiting, HEADACHE and other equivalents of CHILDHOOD MIGRAINE is often related in the literature to a neuro vegetative dysfunction, by which occasional stimuli (environmental, metabolic, emotional) should find a particular somatic expression.",HEADACHE,CHILDHOOD MIGRAINE
503544871,7/16/2014 20:19:59,,1324457633,7/16/2014 20:19:42,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[LOCATION],[LOCATION],syndromes,Na,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/16/2014 20:21:38,,1324458406,7/16/2014 20:20:27,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],syndromes of,N/A,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/16/2014 20:26:33,,1324460549,7/16/2014 20:25:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],rare syndromes of,N/A,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/16/2014 20:30:04,,1324462238,7/16/2014 20:29:37,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],syndromes of,N/A,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/16/2014 20:31:45,,1324462949,7/16/2014 20:31:23,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS,N/A,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/16/2014 22:44:11,,1324519024,7/16/2014 22:43:41,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[IS_A],[IS_A],syndromes of,na,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/16/2014 22:56:56,,1324524212,7/16/2014 22:56:17,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[SYMPTOM],[SYMPTOM],syndromes of,na,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/16/2014 22:58:13,,1324524669,7/16/2014 22:57:33,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],syndromes of,n/a,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/17/2014 00:57:29,,1324591352,7/17/2014 00:57:05,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[SYMPTOM],[SYMPTOM],syndromes of FAMILIAL ADENOMATOUS POLYPOSIS,N/A,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/17/2014 01:15:45,,1324608191,7/17/2014 01:15:31,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CANCER POLYPOSIS,N/A,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/17/2014 01:18:13,,1324610662,7/17/2014 01:17:47,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],rare COLON CANCER syndromes,n/a,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/17/2014 01:36:48,,1324629482,7/17/2014 01:35:45,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",COLON CANCER FAMILIAL ADENOMATOUS POLYPOSIS,n/a,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/17/2014 01:43:23,,1324636116,7/17/2014 01:42:20,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],risk colon cancer is extreme in COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS,N/A,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/17/2014 01:51:39,,1324644199,7/17/2014 01:51:22,bitcoinget,1,21614812,USA,"","",73.39.136.3,[ASSOCIATED_WITH],[ASSOCIATED_WITH],syndromes of,N/A,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544871,7/17/2014 02:07:24,,1324660033,7/17/2014 02:06:42,clixsense,1.0,17548588,CAN,ON,New Hamburg,99.241.226.64,[ASSOCIATED_WITH],[ASSOCIATED_WITH],COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS,n/a,48,74,59,104,-1,RO-has_manifestation,906092-FS1,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
503544872,7/16/2014 20:29:34,,1324462013,7/16/2014 20:29:11,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/16/2014 20:43:23,,1324467533,7/16/2014 20:42:30,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],is treatment of,N/A,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/16/2014 20:50:49,,1324470715,7/16/2014 20:50:26,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],combination,NONE,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/16/2014 21:12:35,,1324482208,7/16/2014 21:11:06,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[OTHER],[OTHER],treatment of,n/a,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/16/2014 21:24:13,,1324487672,7/16/2014 21:23:40,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[TREATS],[TREATS],SULBACTAM AND AMPICILLIN COMBINATION for the treatment of SOFT TISSUE INFECTIONS,N/A,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/16/2014 21:28:16,,1324489427,7/16/2014 21:25:33,clixsense,1.0,15189335,GBR,H9,London,188.29.165.176,[TREATS],[TREATS],effective combination for the treatment,Na,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/16/2014 22:18:20,,1324508334,7/16/2014 22:17:34,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],SULBACTAM AND AMPICILLIN COMBINATION effective combination treatment SOFT TISSUE INFECTIONS,n/a,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/16/2014 22:45:31,,1324519539,7/16/2014 22:45:12,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],the treatment,N/A,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/16/2014 22:56:19,,1324523985,7/16/2014 22:55:48,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],SULBACTAM AND AMPICILLIN COMBINATION treatment of SOFT TISSUE INFECTIONS,N/A,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/16/2014 23:11:14,,1324529132,7/16/2014 23:08:26,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[TREATS],[TREATS],is an effective combination for the treatment of,N/A,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/17/2014 00:26:25,,1324562868,7/17/2014 00:25:55,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],an effective combination for the treatment,N/A,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/17/2014 01:43:39,,1324636405,7/17/2014 01:42:26,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment,n/a,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/17/2014 01:57:57,,1324650459,7/17/2014 01:57:07,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[TREATS],[TREATS],SULBACTAM AND AMPICILLIN COMBINATION SOFT TISSUE INFECTIONS,n/a,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/17/2014 02:22:32,,1324674559,7/17/2014 02:22:03,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],treatment,none,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544872,7/17/2014 04:15:55,,1324784259,7/17/2014 04:15:44,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],treatment,N/A,90,4,111,40,1,RO-may_treat,908272-FS1,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION
503544873,7/16/2014 20:33:35,,1324463628,7/16/2014 20:33:21,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],rare cause of,N?A,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/16/2014 20:36:45,,1324464930,7/16/2014 20:35:21,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[CAUSES],[CAUSES],cause,Na,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/16/2014 20:39:42,,1324466150,7/16/2014 20:39:19,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],and a rare cause of,N/A,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/16/2014 20:44:19,,1324467855,7/16/2014 20:43:34,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],a rare cause of,n/a,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/16/2014 21:47:24,,1324496989,7/16/2014 21:47:12,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[MANIFESTATION],[MANIFESTATION],cause,N/A,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/16/2014 22:36:27,,1324516096,7/16/2014 22:35:51,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[CAUSES],[CAUSES],cause of,na,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/16/2014 23:07:43,,1324527873,7/16/2014 23:07:07,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",cause,n/a,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/16/2014 23:26:17,,1324536064,7/16/2014 23:24:37,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[CAUSES],[CAUSES],rare cause,n/a,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/17/2014 01:17:46,,1324610259,7/17/2014 01:17:35,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[CAUSES],[CAUSES],rare cause of,n/a,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/17/2014 01:59:53,,1324652426,7/17/2014 01:59:05,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[CAUSES],[CAUSES],PHEOCHROMOCYTOMA HYPERTENSION,n/a,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/17/2014 04:19:04,,1324787021,7/17/2014 04:18:53,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[CAUSES],[CAUSES],cause,N/A,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/17/2014 05:27:19,,1324848903,7/17/2014 05:26:24,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,[CAUSES],[CAUSES],cause of,N/A,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/17/2014 05:31:57,,1324852277,7/17/2014 05:31:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],cause of,N/A,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/17/2014 05:35:40,,1324855103,7/17/2014 05:35:15,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[SYMPTOM],[SYMPTOM],a rare cause of,N/A,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544873,7/17/2014 05:38:05,,1324857124,7/17/2014 05:37:26,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[CAUSES],[CAUSES],cause,it is  a rare cause of HYPERTENSION,72,0,83,16,1,RO-disease_may_have_finding,902691-FS1,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
503544874,7/16/2014 20:32:41,,1324463334,7/16/2014 20:32:15,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/16/2014 20:41:51,,1324467033,7/16/2014 20:41:22,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],first reported case of a in a patient with,n/a,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/16/2014 20:49:38,,1324470281,7/16/2014 20:48:45,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[SYMPTOM],[SYMPTOM],a patient,Na,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/16/2014 20:50:25,,1324470560,7/16/2014 20:49:11,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[PREVENTS],[PREVENTS],HAMARTOMA,NONE,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/16/2014 21:43:42,,1324495481,7/16/2014 21:42:39,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[MANIFESTATION],[MANIFESTATION],TONGUE BASE HAMARTOMA with TUBEROUS SCLEROSIS,N/A,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/16/2014 22:34:34,,1324515101,7/16/2014 22:34:04,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[MANIFESTATION],[MANIFESTATION],in a patient,na,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/16/2014 22:37:08,,1324516422,7/16/2014 22:36:17,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[NONE],[NONE],N/A,No related terms can be found.,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/16/2014 23:25:05,,1324535567,7/16/2014 23:24:52,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/17/2014 00:55:42,,1324589424,7/17/2014 00:54:34,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS,N/A,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/17/2014 01:45:47,,1324638323,7/17/2014 01:43:25,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[NONE],[NONE],N/A,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/17/2014 02:06:41,,1324659271,7/17/2014 02:05:13,clixsense,1.0,17548588,CAN,ON,New Hamburg,99.241.226.64,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TONGUE BASE HAMARTOMA a patient with TUBEROUS SCLEROSIS,n/a,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/17/2014 04:19:33,,1324787503,7/17/2014 04:19:05,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/17/2014 04:21:50,,1324789717,7/17/2014 04:20:46,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/17/2014 05:16:42,,1324840127,7/17/2014 05:15:49,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],in a patient with,N/A,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544874,7/17/2014 05:37:26,,1324856524,7/17/2014 05:36:18,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[SYMPTOM],[SYMPTOM],in a patient,because it is first seen in a  patient with TUBEROUS SCLEROSIS,107,67,124,88,-1,RO-cause_of,900150-FS1,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
503544875,7/16/2014 20:24:16,,1324459548,7/16/2014 20:23:59,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES,N/A,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 20:30:44,,1324462567,7/16/2014 20:30:29,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[LOCATION],[LOCATION],FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES,N/A,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 20:31:32,,1324462846,7/16/2014 20:31:13,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],of the,N/A,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 20:45:46,,1324468489,7/16/2014 20:45:27,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],of the,n/a,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 20:55:43,,1324472577,7/16/2014 20:55:16,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",Imaging revealed,Na,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 21:48:55,,1324497529,7/16/2014 21:48:43,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[LOCATION],[LOCATION],of the,N/A,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 21:51:43,,1324498628,7/16/2014 21:51:16,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[LOCATION],[LOCATION],of the,na,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 22:31:13,,1324513798,7/16/2014 22:30:42,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[LOCATION],[LOCATION],Imaging of the,na,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 22:35:46,,1324515755,7/16/2014 22:35:24,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[LOCATION],[LOCATION],of the,N/A,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 22:36:16,,1324516026,7/16/2014 22:35:20,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[NONE],[NONE],N/A,No related terms can be found.,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/16/2014 23:01:32,,1324525686,7/16/2014 23:01:03,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[LOCATION],[LOCATION],of the,n/a,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/17/2014 01:13:32,,1324606472,7/17/2014 01:13:11,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],Imaging revealed of the RENAL ARTERIES,n/a,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/17/2014 01:16:59,,1324609527,7/17/2014 01:16:51,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],of the,N/A,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/17/2014 01:43:16,,1324636014,7/17/2014 01:41:22,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FIBROMUSCULAR DYSPLASIA RENAL ARTERIES,n/a,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544875,7/17/2014 02:05:18,,1324657770,7/17/2014 02:04:19,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[LOCATION],[LOCATION],FIBROMUSCULAR DYSPLASIA RENAL ARTERIES,n/a,48,17,61,40,1,RO-has_finding_site,905441-FS1,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
503544876,7/16/2014 20:23:00,,1324459072,7/16/2014 20:22:43,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],aerosolized,Na,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 20:23:38,,1324459280,7/16/2014 20:23:22,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],treated,N/A,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 20:26:33,,1324460545,7/16/2014 20:26:18,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],responses of BRONCHIAL HYPERREACTIVITY to METHACHOLINE,N/A,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 20:28:10,,1324461372,7/16/2014 20:27:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],to,N/A,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 21:06:35,,1324478303,7/16/2014 21:06:13,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[TREATS],[TREATS],to aerosolized,N/A,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 21:22:53,,1324487023,7/16/2014 21:21:14,clixsense,1.0,15189335,GBR,H9,London,188.29.165.176,[CAUSES],[CAUSES],exhibited much weaker,Na,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 21:33:06,,1324491247,7/16/2014 21:32:31,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",to aerosolized,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 21:55:33,,1324500238,7/16/2014 21:54:51,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,separate,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 22:35:07,,1324515390,7/16/2014 22:34:58,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[NONE],[NONE],N/A,list,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 23:22:34,,1324534280,7/16/2014 23:19:36,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[OTHER],[OTHER],exhibited much weaker responses,n/a,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/16/2014 23:25:38,,1324535769,7/16/2014 23:25:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],to,N/A,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/17/2014 00:57:04,,1324590919,7/17/2014 00:55:43,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[CONTRAINDICATES],[CONTRAINDICATES],exhibited weaker responses of BRONCHIAL HYPERREACTIVITY to aerosolized,N/A,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/17/2014 01:24:08,,1324616386,7/17/2014 01:23:37,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],identically treated,n/a,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/17/2014 01:56:42,,1324649232,7/17/2014 01:55:25,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRONCHIAL HYPERREACTIVITY METHACHOLINE,n/a,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544876,7/17/2014 02:06:03,,1324658613,7/17/2014 02:05:20,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRONCHIAL HYPERREACTIVITY METHACHOLINE,n/a,225,266,249,278,1,RO-may_diagnose,906530-FS1,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
503544877,7/16/2014 20:21:38,,1324458407,7/16/2014 20:21:23,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],"predominantly splenic,",Na,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/16/2014 20:27:00,,1324460800,7/16/2014 20:26:34,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"infected patients THROMBOCYTOPENIA in these patients PLATELET SEQUESTRATION is splenic,",N/A,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/16/2014 20:36:13,,1324464683,7/16/2014 20:35:53,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],in,N/A,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/16/2014 20:37:57,,1324465363,7/16/2014 20:36:33,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in these patients,n/a,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/16/2014 20:39:18,,1324465969,7/16/2014 20:38:34,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"in these patients the is predominantly splenic,",N/A,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/16/2014 20:59:54,,1324474414,7/16/2014 20:58:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],is accelerated,N/A,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/16/2014 21:09:38,,1324480105,7/16/2014 21:08:04,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[MANIFESTATION],[MANIFESTATION],is due,n/a,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/16/2014 21:40:17,,1324494133,7/16/2014 21:38:39,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],is due to,N/A,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/16/2014 23:06:38,,1324527570,7/16/2014 23:06:04,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],due to,n/a,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/16/2014 23:34:59,,1324539722,7/16/2014 23:34:33,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],due to,N/A,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/17/2014 01:01:27,,1324595432,7/17/2014 01:00:39,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[SYMPTOM],[SYMPTOM],in these patients the,N/A,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/17/2014 01:31:34,,1324624210,7/17/2014 01:30:59,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],THROMBOCYTOPENIA PLATELET SEQUESTRATION,n/a,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/17/2014 01:42:25,,1324635140,7/17/2014 01:41:02,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],in these patients,n/a,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/17/2014 02:18:22,,1324670384,7/17/2014 02:17:26,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",THROMBOCYTOPENIA PLATELET SEQUESTRATION,n/a,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544877,7/17/2014 04:21:32,,1324789419,7/17/2014 04:21:15,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,35,118,50,140,-1,RO-has_definitional_manifestation,904751-FS1,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION
503544878,7/16/2014 20:22:41,,1324458911,7/16/2014 20:22:28,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treated with,N/A,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 20:26:04,,1324460356,7/16/2014 20:25:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],was treated with,N/A,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 20:46:55,,1324469022,7/16/2014 20:46:40,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],was treated with,N/A,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 20:51:51,,1324471104,7/16/2014 20:50:51,instagc,1.0,18611009,GBR,Q4,Pershore,31.50.159.84,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],NEOSTIGMINE,NONE,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 21:21:19,,1324486345,7/16/2014 21:20:46,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[TREATS],[TREATS],treated,n/a,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 22:40:56,,1324517984,7/16/2014 22:40:27,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],was treated,N/A,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 22:49:24,,1324521021,7/16/2014 22:49:05,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[TREATS],[TREATS],treated with,na,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 23:00:54,,1324525477,7/16/2014 23:00:34,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],MYASTHENIA GRAVIS was treated with NEOSTIGMINE,N/A,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 23:06:25,,1324527461,7/16/2014 23:05:39,zoombucks,1.0,4688131,CAN,BC,Vancouver,108.180.143.28,[TREATS],[TREATS],was treated with,N/A,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 23:12:57,,1324529829,7/16/2014 23:12:26,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,[TREATS],[TREATS],treated,n/a,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/16/2014 23:17:29,,1324531642,7/16/2014 23:16:45,superrewards,1,26561650,NLD,06,Tilburg,84.87.179.65,[TREATS],[TREATS],treated with NEOSTIGMINE,N/A,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/17/2014 01:15:29,,1324608046,7/17/2014 01:15:22,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],treated,N/A,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/17/2014 01:19:36,,1324611971,7/17/2014 01:19:26,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],was treated with,n/a,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/17/2014 01:53:21,,1324645915,7/17/2014 01:53:10,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treated with,n/a,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544878,7/17/2014 02:02:18,,1324654907,7/17/2014 02:01:28,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],MYASTHENIA GRAVIS NEOSTIGMINE,n/a,23,84,39,95,1,RO-may_diagnose,906775-FS1,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
503544879,7/16/2014 20:21:22,,1324458255,7/16/2014 20:21:07,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],increased bone fragility,Na,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/16/2014 20:28:45,,1324461653,7/16/2014 20:28:19,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],genetic disorder of increased,N/A,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/16/2014 20:37:41,,1324465283,7/16/2014 20:36:55,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],is a genetic disorder of increased bone fragility and,N/A,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/16/2014 20:38:09,,1324465434,7/16/2014 20:37:49,clixsense,1.0,20614047,USA,MO,Maryville,174.32.162.147,[CONTRAINDICATES],[CONTRAINDICATES],forms,asd,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/16/2014 21:21:11,,1324486310,7/16/2014 21:20:10,clixsense,1.0,15189335,GBR,H9,London,188.29.165.176,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",disorder of,Na,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/16/2014 21:50:37,,1324498185,7/16/2014 21:49:47,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[SYMPTOM],[SYMPTOM],genetic disorder of LOW BONE MASS,na,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/16/2014 22:49:04,,1324520895,7/16/2014 22:48:18,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",disorder of,na,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/16/2014 22:54:40,,1324523247,7/16/2014 22:53:46,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],is a genetic disorder of,n/a,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/16/2014 23:35:54,,1324540136,7/16/2014 23:35:34,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SYMPTOM],[SYMPTOM],and,N/A,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/17/2014 01:18:40,,1324611027,7/17/2014 01:18:14,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],genetic disorder of LOW BONE MASS,n/a,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/17/2014 01:26:58,,1324619225,7/17/2014 01:26:11,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]","OSTEOGENESIS IMPERFECTA genetic disorder increased bone fragility LOW BONE MASS Severity varies widely,",N/A,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/17/2014 02:27:23,,1324679350,7/17/2014 02:26:40,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[CAUSES],[CAUSES],OSTEOGENESIS IMPERFECTA LOW BONE MASS,n/a,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/17/2014 02:28:58,,1324681151,7/17/2014 02:28:28,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[MANIFESTATION],[MANIFESTATION],and,none,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/17/2014 04:12:51,,1324781826,7/17/2014 04:12:03,elite,1.0,27788262,USA,"","",172.129.33.133,[IS_A],[IS_A],is a,N/A,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544879,7/17/2014 04:14:46,,1324783441,7/17/2014 04:13:50,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[SYMPTOM],[SYMPTOM],is a genetic disorder of increased bone fragility and LOW BONE MASS,N/a,83,0,95,23,1,RO-disease_has_primary_anatomic_site,902453-FS1,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA
503544880,7/16/2014 20:42:18,,1324467164,7/16/2014 20:41:51,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[MANIFESTATION],[MANIFESTATION],of the large and medium sized,n/a,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/16/2014 21:02:05,,1324475811,7/16/2014 21:00:46,clixsense,1.0,15189335,GBR,H9,London,188.29.165.101,[LOCATION],[LOCATION],large and medium sized JOINTS,Na,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/16/2014 21:08:01,,1324479076,7/16/2014 21:06:06,prodege,1.0,12426026,USA,TX,Trinity,173.184.85.248,[LOCATION],[LOCATION],of the,n/a,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/16/2014 21:39:00,,1324493554,7/16/2014 21:38:32,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[LOCATION],[LOCATION],of the,na,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/16/2014 22:16:22,,1324507559,7/16/2014 22:15:26,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],ARTHRITIS large medium sized JOINTS,n/a,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/16/2014 22:31:39,,1324513947,7/16/2014 22:31:14,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[LOCATION],[LOCATION],of the,na,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/16/2014 22:39:57,,1324517549,7/16/2014 22:39:29,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"Among them,",N/A,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/16/2014 23:05:53,,1324527311,7/16/2014 23:05:04,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[LOCATION],[LOCATION],of the large and medium sized,na,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/16/2014 23:08:25,,1324528155,7/16/2014 23:06:30,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[LOCATION],[LOCATION],ARTHRITIS of medium sized JOINTS,N/A,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/16/2014 23:31:34,,1324538279,7/16/2014 23:31:19,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/17/2014 00:25:11,,1324561899,7/17/2014 00:24:47,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[LOCATION],[LOCATION],of the large and medium sized,N/A,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/17/2014 01:16:00,,1324608539,7/17/2014 01:15:09,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[MANIFESTATION],[MANIFESTATION],the most common include ARTHRITIS of the large and medium sized JOINTS,N/A,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/17/2014 01:17:25,,1324609927,7/17/2014 01:17:19,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],JOINTS,N/A,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/17/2014 01:29:33,,1324622265,7/17/2014 01:29:07,neodev,1.0,21405167,USA,MD,Dundalk,66.87.82.199,[LOCATION],[LOCATION],of the large and medium sized JOINTS,N/A,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544880,7/17/2014 01:30:09,,1324622741,7/17/2014 01:28:37,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[LOCATION],[LOCATION],large medium sized,not applicable,76,36,81,45,1,RO-has_finding_site,905445-FS1,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS
503544881,7/16/2014 20:25:31,,1324460099,7/16/2014 20:25:03,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],immune cells infiltrating,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/16/2014 21:07:51,,1324478972,7/16/2014 21:07:31,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[LOCATION],[LOCATION],infiltrating,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/16/2014 21:48:18,,1324497310,7/16/2014 21:46:46,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[PART_OF],[PART_OF],PANCREATIC ISLETS in INSULIN DEPENDENT DIABETES MELLITUS,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/16/2014 22:32:33,,1324514266,7/16/2014 22:32:09,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are important mediators,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/16/2014 22:37:05,,1324516367,7/16/2014 22:36:51,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.172,[TREATS],[TREATS],important mediators,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 00:32:07,,1324567603,7/17/2014 00:30:39,clixsense,1.0,21418111,CAN,ON,Guelph,99.225.13.106,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",important mediators beta cell destruction,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 01:09:26,,1324602734,7/17/2014 01:08:44,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],important mediators of beta cell destruction,n/a,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 01:15:13,,1324607738,7/17/2014 01:15:01,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],ISLETS,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 01:39:16,,1324632190,7/17/2014 01:38:23,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PANCREATIC ISLETS INSULIN DEPENDENT DIABETES MELLITUS,n/a,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 02:11:06,,1324663563,7/17/2014 02:09:26,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],in,n/a,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 02:29:34,,1324681610,7/17/2014 02:28:42,rewardsspot,1.0,17763704,USA,IL,Chicago,67.212.175.123,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PANCREATIC ISLETS DEPENDENT DIABETES,n/a,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 04:16:37,,1324784880,7/17/2014 04:16:22,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],mediators,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 04:31:50,,1324798913,7/17/2014 04:31:12,elite,1.0,27788262,USA,"","",172.129.33.133,[TREATS],[TREATS],are important mediators of beta cell destruction in,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 05:04:09,,1324828531,7/17/2014 05:01:14,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",Cytokines PANCREATIC ISLETS INSULIN DEPENDENT DIABETES MELLITUS,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544881,7/17/2014 05:26:18,,1324848109,7/17/2014 05:25:25,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],infiltrating,N/A,48,118,64,153,1,RO-disease_has_primary_anatomic_site,902058-FS1,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
503544882,7/16/2014 20:27:36,,1324461098,7/16/2014 20:26:41,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,[SYMPTOM],[SYMPTOM],due to,n/a,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 20:31:41,,1324462936,7/16/2014 20:31:01,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",due to,N/A,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 20:34:54,,1324464158,7/16/2014 20:34:33,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],due to,N/A,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 20:40:10,,1324466304,7/16/2014 20:39:43,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],due to,N/A,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 20:47:31,,1324469279,7/16/2014 20:46:50,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],presented with,N/A,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 20:59:42,,1324474295,7/16/2014 20:59:07,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,[CAUSES],[CAUSES],with HEADACHE MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.,N/A,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 21:09:42,,1324480162,7/16/2014 21:09:21,instagc,1.0,28301350,GBR,O4,Torquay,92.23.66.130,[CAUSES],[CAUSES],CAUSING,N/A,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 21:27:25,,1324489112,7/16/2014 21:26:12,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",HEADACHE due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.,N/A,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 21:45:40,,1324496349,7/16/2014 21:45:07,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.61,[NONE],[NONE],na,separate conditions,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 22:35:50,,1324515783,7/16/2014 22:35:09,bitcoinget,1.0,28222930,USA,IL,Mattoon,206.166.56.30,[CAUSES],[CAUSES],due to,na,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 22:59:14,,1324524948,7/16/2014 22:58:15,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",presented due to,n/a,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/16/2014 23:07:13,,1324527720,7/16/2014 23:06:41,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[CAUSES],[CAUSES],due to,na,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/17/2014 00:54:33,,1324588444,7/17/2014 00:53:30,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[SYMPTOM] [PREVENTS],"[PREVENTS]
[SYMPTOM]","presented with HEADACHE unsteadiness, diplopia and papilloedema",N/A,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/17/2014 01:09:45,,1324603024,7/17/2014 01:09:26,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],due to,n/a,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544882,7/17/2014 01:13:07,,1324606115,7/17/2014 01:13:01,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],HEADACHE,N/A,66,122,73,187,1,RO-disease_may_have_finding,902730-FS1,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS
503544883,7/16/2014 20:31:38,,1324462899,7/16/2014 20:31:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],none showed an increase in the,N/A,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/16/2014 20:35:22,,1324464327,7/16/2014 20:34:55,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],who had increase in,N/A,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/16/2014 21:21:43,,1324486486,7/16/2014 21:21:13,elite,1.0,28276268,USA,TX,Houston,70.140.36.33,[MANIFESTATION],[MANIFESTATION],showed decreased,[MANIFESTATION],232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/16/2014 21:45:30,,1324496258,7/16/2014 21:43:42,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[MANIFESTATION],[MANIFESTATION],metastatic lesions in patients who had LYMPH NODE METASTASIS,N/A,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/16/2014 22:15:25,,1324507106,7/16/2014 22:14:27,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",LYMPH NODE METASTASIS showed decreased increase METASTATIC LESIONS.,n/a,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/16/2014 22:40:47,,1324517959,7/16/2014 22:40:15,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]",showed an increase,N/A,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/16/2014 22:49:02,,1324520882,7/16/2014 22:48:19,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was compared between,N/A,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/16/2014 23:00:02,,1324525243,7/16/2014 22:59:31,zoombucks,1.0,9383666,USA,IN,Fishers,108.71.210.230,[NONE],[NONE],na,two unrelated items,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/16/2014 23:34:31,,1324539503,7/16/2014 23:34:17,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],who had,N/A,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/17/2014 01:16:37,,1324609177,7/17/2014 01:15:55,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients who had LYMPH NODE METASTASIS showed an increase in,n/a,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/17/2014 01:21:52,,1324613899,7/17/2014 01:21:15,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[PREVENTS],[PREVENTS],and none (0%) showed an increase,N/A,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/17/2014 02:24:59,,1324676906,7/17/2014 02:24:40,prodege,1.0,13795372,CAN,NS,Halifax,24.222.85.98,[TREATS],[TREATS],showed,none,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/17/2014 03:50:54,,1324761593,7/17/2014 03:49:39,neodev,1.0,20929875,USA,MA,Boston,96.233.18.114,[NONE],[NONE],N/A,none (0%) showed an increase in the METASTATIC LESIONS,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/17/2014 04:10:30,,1324779763,7/17/2014 04:09:00,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[PART_OF],[PART_OF],metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS,N/a,232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544883,7/17/2014 04:29:53,,1324796907,7/17/2014 04:28:28,elite,1.0,27788262,USA,"","",172.129.33.133,[NONE],[NONE],N/A,"LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",232,102,249,123,-1,RO-disease_has_finding,901642-FS1,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
503544884,7/16/2014 20:25:31,,1324460095,7/16/2014 20:25:19,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],trial.,Na,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/16/2014 21:23:39,,1324487416,7/16/2014 21:22:59,eup_slw,1.0,20900720,USA,ID,Boise,97.121.0.39,[TREATS],[TREATS],AMPHOTERICIN B for CRYPTOCOCCAL MENINGITIS randomized trial.,N/A,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/16/2014 22:46:08,,1324519810,7/16/2014 22:45:33,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared with,N/A,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 00:23:05,,1324560531,7/17/2014 00:22:35,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[TREATS],[TREATS],for,N/A,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 01:13:11,,1324606163,7/17/2014 01:12:54,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],a randomized trial.,n/a,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 01:19:12,,1324611477,7/17/2014 01:18:09,bitcoinget,1.0,27806000,USA,TX,San Antonio,67.11.143.200,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS,N/A,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 01:28:36,,1324621125,7/17/2014 01:26:51,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],for,not applicable,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 02:12:34,,1324664969,7/17/2014 02:11:45,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],randomized trial.,n/a,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 02:19:12,,1324671241,7/17/2014 02:18:43,clixsense,1.0,17548588,CAN,ON,New Hamburg,99.241.226.64,[TREATS],[TREATS],AMPHOTERICIN B for CRYPTOCOCCAL MENINGITIS,n/a,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 04:14:33,,1324783275,7/17/2014 04:14:05,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,[TREATS],[TREATS],for,"because of:

AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS",62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 04:17:57,,1324786028,7/17/2014 04:17:44,zoombucks,1.0,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],trial.,N/A,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 05:23:42,,1324846142,7/17/2014 05:23:09,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],for,N/A,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 05:40:53,,1324859292,7/17/2014 05:40:17,neodev,1.0,14861092,GBR,H9,London,90.194.156.173,[PART_OF],[PART_OF],for,N/A,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 06:45:32,,1324915077,7/17/2014 06:45:00,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[ASSOCIATED_WITH]",compared with,na,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
503544884,7/17/2014 06:49:47,,1324919042,7/17/2014 06:48:29,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,[OTHER],[OTHER],compared with,N/a,62,26,84,40,1,RO-may_treat,907508-FS1,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
